Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Articles

Page Path
HOME > Cancer Res Treat > Volume 43(1); 2011 > Article
Special Article Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2008
Kyu-Won Jung, MS1, Sohee Park, PhD1, Hyun-Joo Kong, MS1, Young-Joo Won, PhD1, Joo Young Lee, MD1, Eun-Cheol Park, MD, PhD2, Jin-Soo Lee, MD, PhD1
Cancer Research and Treatment : Official Journal of Korean Cancer Association 2011;43(1):1-11.
DOI: https://doi.org/10.4143/crt.2011.43.1.1
Published online: March 31, 2011

1The Korea Central Cancer Registry, Division of Cancer Registration and Surveillance, National Cancer Center, Goyang, Korea.

2National Cancer Control Institute, National Cancer Center, Goyang, Korea.

Correspondence: Sohee Park, PhD. The Korea Central Cancer Registry, Division of Cancer Registration and Surveillance, National Cancer Center, Madu 1-dong, Ilsandong-gu, Goyang 410-769, Korea.
Tel: 82-31-920-2015, Fax: 82-31-920-2179, shpark@ncc.re.kr
• Received: February 22, 2011   • Accepted: March 3, 2011

Copyright © 2011 by the Korean Cancer Association

This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 18,494 Views
  • 106 Download
  • 203 Crossref
  • 198 Scopus
next
  • Purpose
    This paper overviews the nationwide cancer statistics including incidence, mortality, survival and prevalence, and their trends in Korea based on the year 2008 cancer incidence data.
  • Materials and Methods
    Incidence data from 1993 to 2008 were obtained from the Korea National Cancer Incidence Database, and the vital status was followed through December 31, 2009. Mortality data from 1983 to 2008 were obtained from the Korea National Statistics Office. Crude rates and age-standardized rates for incidence, mortality, prevalence and relative survival were calculated.
  • Results
    There were 178,816 cancer cases and 68,912 cancer deaths observed during year 2008 and 724,663 10-year cancer prevalent cases as of January 1, 2009 in Korea. The incidence rate for all cancer combined showed an annual increase of 3.1% from 1999 to 2008.
  • Conclusion
    With significantly increasing cancer incidence, Korea faces a large cancer burden and efficient cancer control programs are essential.
Cancer has been the leading cause of death in Korea since 1983 [1] and has drawn much attention in public health. Over 170,000 new cancer cases are diagnosed annually in Korea and one out of four deaths results from cancer [2,3]. This paper gives an overview of the nationwide cancer statistics, including the incidence, mortality, prevalence, survival rates and their trends in Korea.
1. Data sources
The Ministry of Health and Welfare, Korea had initiated a nationwide hospital-based cancer registry as early as 1980 called the Korea Central Cancer Registry (KCCR). The registry collected approximately 80-90% cancer cases from more than 150 training hospitals across the country every year. From 1999, the KCCR expanded cancer registration to cover the whole population under the Population-Based Regional Cancer Registry (PB-RCR) program. Details of the history, objectives, and activities of the KCCR have been documented [4]. Incidence data from 1999 to 2008 were obtained from the Korea National Cancer Incidence Database (KNCI DB). Cancer cases were classified according to the International Classification of Diseases for Oncology 3rd edition [5] and converted according to the International Classification of Diseases 10th edition (ICD-10) [6]. The survival analysis used 1,623,046 cancer cases first diagnosed during 1993-2008 from the KNCI DB, and followed the vital status through 31 December 2009.
Mortality data from 1983 to 2008 were obtained from the Korea National Statistics Office (KNSO) [1]. Cause of death was coded and classified according to the ICD-10. The population data were also obtained from KNSO using the resident registration population on July 1st of specified years.
Crude rates (CRs) and age-specific rates of cancer incidence and mortality were calculated. Age-standardized rates (ASRs) were determined using the World Health Organization (WHO) world standard population [7]. The cumulative risks of cancer incidence, which represent the probability of developing cancer to life expectancy, were also calculated. Changes in the annual age-standardized cancer incidence rates were examined by calculating the annual percentage change over a time period as (exp(b)-1)x100, where b is the slope of the regression of log ASR on a calendar year [8].
In order to assess the level of cancer burden, prevalence was also estimated which represents new and pre-existing cancer cases diagnosed during a given period of time and still alive on an index date. Using the cancer incidence database from 1999 to 2008, we calculated the limited-duration prevalence, such as 1, 5, and 10-year prevalence. In this study, for example, 10-year prevalence was calculated from the number of people alive on January 1, 2009 who were diagnosed with cancer within the previous 10 years. We applied the counting method using SEER*Stat software [9] to calculate the number of prevalent cases while adjusting for the patients lost in follow-up [8].
The survival duration of each case was determined as the time difference between the date of initial diagnosis and the date of death, date of loss to follow-up, or closing date for follow-up. Observed survival rates were calculated using a life table method and relative survival rates were examined with the Ederer II method [10] using an algorithm written in SAS by Dickman [11], with some minor modifications.
1. Incidence
Table 1 presents the overall number of cancer incident cases, deaths and prevalent cases during 2008 in Korea by sex and cancer site. In 2008, 178,816 cancer incident cases and 68,912 deaths were observed in Korea. As of January 1, 2009, there were 724,663 10-year cancer prevalent cases observed in Korea. The cumulative risks for developing cancer to the life expectancy were 37.2% for men and 30.5 for women in 2008.
Table 2 shows the cancer incidence rates by sex in 2008. The CRs of all sites combined in 2008 were 375.7 and 348.1 per 100,000 in men and women, respectively. The ASRs of all sites combined were 318.5 and 245.3 per 100,000 in men and women, respectively. In males, the five leading primary sites of cancer were the stomach (CR, 76.3; ASR, 63.8), colon and rectum (CR, 54.7; ASR, 45.9), lung (CR, 54.1; ASR, 46.9), liver (CR, 47.6; ASR, 38.9), and prostate (CR, 26.1; ASR, 23.0), accounting for 68.9% of all newly diagnosed cancers in 2008. In females, the most common cancer sites were the thyroid (CR, 91.9; ASR, 68.6), breast (CR, 51.1; ASR, 36.8), stomach (CR, 37.2; ASR, 24.9), colon and rectum (CR, 36.9; ASR, 24.7), lung (CR, 21.9; ASR, 13.9), and cervix uteri (CR, 15.8; ASR, 11.2), accounting for 73.2% of all newly diagnosed cancers. Thyroid cancer alone accounted for 26.4% (22,648) of incident cases in women in 2008.
2. Mortality
There were 68,912 cancer deaths reported in Korea during 2008, accounting for 28.0% of all deaths (Table 3). In 2008, The CRs of all sites combined were 176.9 and 101.9 per 100,000 for men and women, respectively. The ASRs of all sites combined were 154.1 and 63.5 per 100,000 for men and women, respectively. Cancers of the lung, liver, stomach and colon and rectum were the most common fatal cancers, which accounted for about 62.7% of all cancer deaths in 2008 (Table 4).
In men, the five leading primary cancer sites for mortality in 2008 were the lung (CR, 44.0; ASR, 38.7), liver (CR, 34.4; ASR, 28.5), stomach (CR, 27.1; ASR, 23.5), colon and rectum (CR, 15.4; ASR, 13.5), and pancreas (CR, 8.6; ASR, 7.5). In women, lung cancer mortality (CR, 15.8; ASR, 9.4) increased gradually being the first cancer site for mortality in 2008, followed by stomach (CR, 14.6; ASR, 8.7), colon and rectum (CR, 12.1; ASR, 7.3), liver (CR, 11.3; ASR, 7.2), and gallbladder (CR, 7.1; ASR, 4.1).
3. Trends in cancer incidence
Tables 5-7 present the cancer incidence rates during 1999-2008 in Korea for all sites combined and for selected cancer sites. The incidence rate for all sites combined increased by 3.1% annually from 1999 to 2008. The incidence rate for all sites combined increased by 1.5% annually in men and by 5.1% in women from 1999 to 2008. The rapid increase in cancer incidence is also illustrated in Fig. 1.
As shown in Fig. 2, the incidence rates have continued to increase for colon and rectum and thyroid cancer in both sexes, along with breast cancer in females and prostate cancer in males. On the contrary, the incidences of liver cancer in both sexes and cervix cancer in women have decreased. Stomach cancer incidence rates remained the same in men and women. One notable aspect was the sharp increase (25.4% annually) in the incidence of female thyroid cancer. As diagnostic techniques for thyroid cancer have become more sensitive, such as with the advent of ultrasound and fine-needle aspiration, the detection of subclinical disease has become possible. Therefore, the increased incidence of thyroid cancer may reflect improved diagnostic techniques for previously undetected disease, rather than a true increase in the occurrence of thyroid cancer [12,13]. Furthermore, from the construction of a KNCI DB for 1999 onward to 2008, the completeness of the Korea cancer registry data has improved gradually. This might have contributed in part to the gradual overall increase in cancer incidence, especially among the elderly.
4. Age-specific incidence rates for selected cancer sites
Table 8 presents the most common cancer sites by sex and age group in 2008. Leukemia and thyroid were the most common forms in both sexes, for ages 0-14 and 15-34 years, respectively. For males, stomach cancer was the most common in 35-64-year-olds, while lung cancer was more frequent for patients aged 65 and over. Thyroid cancer was the most common site for mid-aged Korean women (35-64-year-olds), and colorectal cancer was the most common among old aged women (≥65 year-olds).
Fig. 3 shows the age-specific incidence rates of the selected cancers for men and women in 2008. The data show that the incidence of stomach, lung, liver and colorectal cancers increased gradually with age. Female breast and thyroid cancers showed highest incidence rates for women in their late forties and early fifties, respectively, and then leveled off. This pattern is very different from the rates observed in Western countries [14].
5. Trends in cancer mortality
Figs. 1 and 4 show the trends in cancer deaths for all sites combined and for selected cancer sites. Age-standardized mortality rates have decreased for all sites combined in both sexes since 2002. Lung cancer surpassed stomach cancer as the leading cause of cancer death in 1999, and is expected to account for 21.5% of all cancer deaths in 2008. The age-standardized mortality rates of lung have decreased slightly for men since 2001, but increased in women. The age-standardized mortality rates of stomach and cervix uteri cancer have decreased continuously. Along with the significant increases in colorectal, prostate and female breast cancer incidence, the mortality rates of these cancers have also continued to increase.
6. Survival rates
Table 9 shows the 5-year relative survivals for four periods of diagnosis time: 1993-1995, 1996-2000, 2001-2005 and 2004-2008. Cancer patients that were diagnosed in the recent period (2004-2008) had 5-year relative survival rates of 59.5% for all sites combined in both sexes, 50.8% in males and 69.2% in females. When compared with earlier periods, notable improvements have been observed in the 5-year relative survival rates for all sites combined. Observation of higher female cancer survival rates than male cancer survival rates may be partly explained by common female cancers (e.g., thyroid, breast, and uterine cervix) that are known to have relatively good prognoses.
When examined by the year of diagnosis and cancer site, the 5-year relative survival rates appeared to be higher for most major cancer sites in patients diagnosed during 2004-2008 compared to 1993-1995, except for pancreatic cancer. The greatest improvements were seen in prostate, stomach, leukemia, and non-Hodgkin lymphoma. The improving survival rates could be attributable to early detection, as well as to improved treatments [15,16], but this needs to be evaluated further. Lack of progress in early detection and treatment could explain the observed absence of improvement in the survival rate of pancreatic cancer [17].
7. Prevalence rates
Table 10 shows the 10-year cancer prevalent rates on January 1, 2009 in Korea by sex and cancer site. The 10-year cancer prevalence CRs of all sites combined were 1,350.4 and 1,583.7 per 100,000 in men and women, respectively, and the 10-year cancer prevalence ASRs of all sites combined were 1,145.0 and 1,136.2 per 100,000 in men and women, respectively. In males, the five leading primary sites of cancer for prevalence were the stomach (CR, 362.0; ASR, 302.0), colon and rectum (CR, 244.2; ASR, 206.1), liver (CR, 109.4; ASR, 90.2), prostate (CR, 96.7; ASR, 86.3), and lung (CR, 94.8; ASR, 81.1), accounting for 67.2% of all cancer prevalent cases. In females, the most common cancer sites were the thyroid (CR, 375.1; ASR, 277.7), breast (CR, 320.9; ASR, 232.2), stomach (CR, 183.0; ASR, 123.6), colon and rectum (CR, 172.8; ASR, 115.8), cervix uteri (CR, 134.3; ASR, 95.1), and lung (CR, 46.5; ASR, 31.2), accounting for 77.8% of all cancer prevalent cases.
Fig. 5 shows the prevalence by time since diagnosis. For all cancers combined, the 1- to 2-year prevalence represented 37% of the total prevalent cases. The 1- to 2-year prevalence as a percentage of the total was highest for thyroid cancer (18%) following stomach (16%), and colorectal cancer (14%), which has high incidence rates and a good prognosis. For all cancers combined, the 2- to 5-year prevalence and the 5- to 10-year prevalence constituted 33% and 30% of the total prevalence in both sexes, respectively. The long-term prevalence of lung and liver cancer was relatively low due to lower rates of survival.
Acknowledgements
The authors thank the Korea Central Cancer Registry (KCCR)-affiliated Hospitals, non KCCR-affiliated Hospitals, 11 Regional Cancer Registries (Busan, Daegu & Gyeongbuk, Gwangju & Jeonnam, Incheon, Daejeon & Chungnam, Ulsan, Gangwon, Chungbuk, Jeonbuk, Gyeongnam, and Jejudo), the National Health Insurance Corporation, and the National Statistical Office for data collection.
This work was supported by a research grant from the National Cancer Center (No. 1010160), and the National Health Promotion Program grant (No. 1060300) from the Ministry of Health and Welfare, Republic of Korea.

Conflict of interest relevant to this article was not reported.

  • 1. National Statistical Office, 2009 [Internet]. 2009. cited 2011 Jan 14Daejeon: National Statistical Office; Available from: http://kostat.go.kr
  • 2. Ministry for Heath, Welfare and Family AffairsAnnual report of cancer incidence (2006) and survival (1993-2006) in Korea. 2009. Seoul: Ministry for Heath, Welfare and Family Affairs.
  • 3. Won YJ, Sung J, Jung KW, Kong HJ, Park S, Shin HR, et al. Nationwide cancer incidence in Korea, 2003-2005. Cancer Res Treat. 2009;41:122–131. PMID: 19809561ArticlePubMedPMCPDF
  • 4. Shin HR, Won YJ, Jung KW, Kong HJ, Yim SH, Lee JK, et al. Nationwide cancer incidence in Korea, 1999~2001; first result using the national cancer incidence database. Cancer Res Treat. 2005;37:325–331. PMID: 19956367ArticlePubMedPMCPDF
  • 5. Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, et al. International classification of diseases for oncology. 2000. 3rd ed. Geneva: World Health Organization.
  • 6. World Health OrganizationManual of the international statistical classification of diseases, injuries, and causes of death. 1992. 10th rev. Geneva: World Health Organization.
  • 7. Segi M. Cancer mortality for selected sites in 24 countries (1950-1957). 1960. Sendai: Tohoku University School of Medicine.
  • 8. Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W. SEER cancer statistics review, 1975-2007. 2010. Bethesda, MD: National Cancer Institute.
  • 9. SEER*Stat Program, version 6.6.1 [Internet]. National Cancer Institute. 2011. cited 2011 Jan 14Bethsda, MD: National Cancer Institute; Available from: http://seer.cancer.gov/seerstat/
  • 10. Ederer F, Heise H. Instructions to IBM programmers in processing survival computations. Methodological note No. 10. 1959. Bethesda, MD: National Cancer Institute.
  • 11. Dickman P [Internet]. cited 2009 Apr 14Stockholm: PaulDickman.com; Available from: http//www.pauldickman.com
  • 12. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA. 2006;295:2164–2167. PMID: 16684987ArticlePubMed
  • 13. Enewold L, Zhu K, Ron E, Marrogi AJ, Stojadinovic A, Peoples GE, et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. Cancer Epidemiol Biomarkers Prev. 2009;18:784–791. PMID: 19240234ArticlePubMedPMC
  • 14. Curado MP, Edwards B, Shin HR, Stom H, Ferlay J, Heanue M. Cancer incidence in five continents. 2007. vol.9. Lyon: IARC.
  • 15. Jung KW, Yim SH, Kong HJ, Hwang SY, Won YJ, Lee JK, et al. Cancer survival in Korea 1993-2002: a population-based study. J Korean Med Sci. 2007;22(Suppl):S5–S10. PMID: 17923755ArticlePubMedPMC
  • 16. Gondos A, Bray F, Hakulinen T, Brenner H. Trends in cancer survival in 11 European populations from 1990 to 2009: a model-based analysis. Ann Oncol. 2009;20:564–573. PMID: 19066327ArticlePubMed
  • 17. Dickman PW, Adami HO. Interpreting trends in cancer patient survival. J Intern Med. 2006;260:103–117. PMID: 16882274ArticlePubMed
Fig. 1
Annual age-standardized cancer incidence and death rates for all sites by sex during 1983-2008 in Korea. Age-standardization was based on the World Health Organization (WHO) world standard population.
crt-43-1-g001.jpg
Fig. 2
Trend of age-standardized cancer incidence for selected cancers by sex during 1999-2008 in Korea. Age-standardization was based on the World Health Organization (WHO) world standard population. (A) Male. (B) Female.
crt-43-1-g002.jpg
Fig. 3
Age-specific incidence rates of major cancers during 2008 in Korea. (A) Male. (B) Female.
crt-43-1-g003.jpg
Fig. 4
Annual age-standardized cancer mortality for selected cancers by sex during 1983-2008 in Korea. Age-standardization was based on the World Health Organization (WHO) world standard population. (A) Male. (B) Female.
crt-43-1-g004.jpg
Fig. 5
Number of prevalent cases by time since diagnosis for major cancer sites on January 1, 2009 in Korea.
crt-43-1-g005.jpg
Table 1
Number of cancer incidence cases, deaths, and prevalent cases by sex during 2008 in Korea
Sites New cases Deaths 10-yr prevalent cases a)



Both sexes Male Female Both sexes Male Female Both sexes Male Female
All sites 178,816 93,017 85,799 68,912 43,785 25,127 724,663 334,329 390,334
Lip, oral cavity, and pharynx 2,557 1,899 658 969 761 208 11,304 7,728 3,576
Esophagus 2,181 1,986 195 1,385 1,244 141 5,216 4,717 499
Stomach 28,078 18,898 9,180 10,312 6,712 3,600 134,722 89,616 45,106
Colon and rectum 22,623 13,536 9,087 6,802 3,809 2,993 103,033 60,448 42,585
Liver 15,663 11,776 3,887 11,292 8,512 2,780 36,036 27,085 8,951
Gallbladder b) 4,378 2,149 2,229 3,459 1,698 1,761 9,935 5,076 4,859
Pancreas 4,320 2,404 1,916 3,767 2,135 1,632 4,780 2,663 2,117
Larynx 1,073 998 75 409 364 45 6,385 5,977 408
Lung 18,774 13,384 5,390 14,791 10,899 3,892 34,926 23,465 11,461
Breast 12,659 75 12,584 1,731 13 1,718 79,468 381 79,087
Cervix uteri 3,888 - 3,888 954 - 954 33,102 - 33,102
Corpus uteri 1,562 - 1,562 210 - 210 9,084 - 9,084
Ovary 1,816 - 1,816 834 - 834 9,732 - 9,732
Prostate 6,471 6,471 - 1,168 1,168 - 23,940 23,940 -
Testis 176 176 - 14 14 - 1,408 1,408 -
Kidney 3,228 2,220 1,008 655 461 194 15,243 10,265 4,978
Bladde 3,230 2,582 648 1,007 752 255 18,260 14,845 3,415
Brain and CNS 1,620 876 744 1,040 568 472 6,273 3,289 2,984
Thyroid 26,923 4,275 22,648 347 108 239 107,693 15,252 92,441
Hodgkin lymphoma 210 127 83 46 31 15 1,253 796 457
Non-Hodgkin lymphoma 3,475 1,936 1,539 1,343 814 529 16,142 8,873 7,269
Multiple myeloma 893 480 413 615 316 299 2,464 1,295 1,169
Leukemia 2,561 1,432 1,129 1,507 867 640 9,936 5,442 4,494
Other and ill-defined 10,457 5,337 5,120 4,255 2,539 1,716 44,328 21,768 22,560

CNS, central nervous system. a)10-yr prevalent cases: limited-duration prevalent cases on January 1, 2009. These are patients that were diagnosed between January 1, 1999 and December 31, 2008 and were alive on January 1, 2009. Multiple primary cancer cases were counted multiple times, b)Includes gallbladder and other/unspecified parts of biliary tract.

Table 2
Crude and age-standardized cancer mortality rates by sex during 2008 in Korea
Sites Crude incidence rates/100,000 Age-standardized incidence rates/100,000 a)


Both sexes Male Female Both sexes Male Female
All sites 361.9 375.7 348.1 271.1 318.5 245.3
Lip, oral cavity, and pharynx 5.2 7.7 2.7 3.9 6.4 1.9
Esophagus 4.4 8.0 0.8 3.3 6.9 0.5
Stomach 56.8 76.3 37.2 42.2 63.8 24.9
Colon and rectum 45.8 54.7 36.9 34.1 45.9 24.7
Liver 31.7 47.6 15.8 23.7 38.9 10.5
Gallbladder b) 8.9 8.7 9.0 6.4 7.5 5.5
Pancreas 8.7 9.7 7.8 6.3 8.3 4.8
Larynx 2.2 4.0 0.3 1.6 3.4 0.2
Lung 38.0 54.1 21.9 27.7 46.9 13.9
Breast 25.6 0.3 51.1 18.7 0.3 36.8
Cervix uteri 7.9 - 15.8 5.8 - 11.2
Corpus uteri 3.2 - 6.3 2.4 - 4.6
Ovary 3.7 - 7.4 2.8 - 5.5
Prostate 13.1 26.1 - 9.6 23.0 -
Testis 0.4 0.7 - 0.4 0.7 -
Kidney 6.5 9.0 4.1 5.0 7.4 3.0
Bladder 6.5 10.4 2.6 4.7 9.0 1.6
Brain and CNS 3.3 3.5 3.0 2.9 3.3 2.6
Thyroid 54.5 17.3 91.9 40.8 13.1 68.6
Hodgkin lymphoma 0.4 0.5 0.3 0.4 0.5 0.3
Non-Hodgkin lymphoma 7.0 7.8 6.2 5.5 6.7 4.6
Multiple myeloma 1.8 1.9 1.7 1.4 1.6 1.2
Leukemia 5.2 5.8 4.6 5.0 5.7 4.3
Other and ill-defined 21.2 21.6 20.8 16.5 19.1 4.3

CNS, central nervous system. a)Age adjusted to the World Health Organization (WHO) world standard population, b)Includes gallbladder and other/unspecified parts of biliary tract.

Table 3
Ten leading causes of death during 2008 in Korea
Rank Cause of deaths No. of death Percent of all deaths Age-standardized death rate a)
All causes 246,113 100 365.3
1 Cancer 68,912 28 101.0
2 Cerebrovascular disease 27,932 11.3 39.1
3 Heart disease 21,429 8.7 30.6
4 Intentional self harm (suicide) 12,858 5.2 20.3
5 Diabetes mellitus 10,234 4.2 14.5
6 Chronic lower respiratory diseases 7,338 3.0 10.1
7 Transport accidents 7,287 3.0 12.1
8 Disease of liver 7,164 2.9 10.7
9 Pneumonia 5,461 2.2 7.7
10 Hypertensive diseases 4,724 1.9 6.6
Others 72,774 29.6 112.6

Source: Mortality Data, 2008, Korea National Statistical Office. a)Age adjusted to the World Health Organization (WHO) world standard population.

Table 4
Crude and age-standardized cancer mortality rates by sex during 2008 in Korea
Sites Crude mortality rates/100,000 Age-standardized mortality rates/100,000 a)


Both sexes Male Female Both sexes Male Female
All sites 139.5 176.9 101.9 101.0 154.1 63.5
Lip, oral cavity, and pharynx 2.0 3.1 0.8 1.4 2.6 0.5
Esophagus 2.8 5.0 0.6 2.1 4.4 0.3
Stomach 20.9 27.1 14.6 14.8 23.5 8.7
Colon and rectum 13.8 15.4 12.1 9.8 13.5 7.3
Liver 22.9 34.4 11.3 16.9 28.5 7.2
Gallbladder b) 7.0 6.9 7.1 4.9 6.1 4.1
Pancreas 7.6 8.6 6.6 5.5 7.5 4.0
Larynx 0.8 1.5 0.2 0.6 1.3 0.1
Lung 29.9 44.0 15.8 21.3 38.7 9.4
Breast 3.5 0.1 7.0 2.6 0.0 4.9
Cervix uteri 1.9 - 3.9 1.4 - 2.5
Corpus uteri 0.4 - 0.9 0.3 - 0.6
Ovary 1.7 - 3.4 1.2 - 2.3
Prostate 2.4 4.7 - 1.6 4.6 -
Testis 0.0 0.1 - 0.0 0.1 -
Kidney 1.3 1.9 0.8 1.0 1.6 0.5
Bladder 2.0 3.0 1.0 1.4 2.8 0.5
Brain and CNS 2.1 2.3 1.9 1.7 2.0 1.4
Thyroid 0.7 0.4 1.0 0.5 0.4 0.5
Hodgkin lymphoma 0.1 0.1 0.1 0.1 0.1 0.0
Non-Hodgkin lymphoma 2.7 3.3 2.1 2.0 2.8 1.4
Multiple myeloma 1.2 1.3 1.2 0.9 1.1 0.8
Leukemia 3.1 3.5 2.6 2.6 3.2 2.0
Other and ill-defined 8.6 10.3 7.0 6.3 9.1 4.4

CNS, central nervous system. a)Age adjusted to the World Health Organization (WHO) world standard population, b)Includes gallbladder and other/unspecified parts of biliary tract.

Table 5
Trends in cancer incidence rates in both sexes during 1999-2008 in Korea
Sites Year APC a)

1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
All sites 210.5 205.1 216.7 220.1 227.1 234.1 246.7 250.5 260.8 271.1 3.1 b)
Lip, oral cavity, and pharynx 3.6 4.4 3.6 3.7 3.8 3.8 3.8 3.7 3.8 3.9 0.1
Esophagus 4.1 3.7 3.9 3.8 3.6 3.5 3.5 3.4 3.3 3.3 -2.1 b)
Stomach 43.6 42.3 44.0 43.6 43.2 41.1 44.3 42.7 41.6 42.2 -0.3
Colon and rectum 20.4 21.0 22.9 24.7 26.8 28.5 30.8 32.2 33.3 34.1 6.4 b)
Liver 27.9 26.7 27.3 26.5 25.7 25.5 25.8 24.5 24.2 23.7 -1.7 b)
Gallbladder c) 6.5 6.4 6.7 6.7 6.7 6.9 7.1 6.6 6.5 6.4 0.1
Pancreas 5.6 5.5 5.5 5.8 5.8 6.0 6.3 6.1 6.3 6.3 1.7
Larynx 2.3 2.2 2.4 2.2 2.1 1.9 2.0 1.8 1.8 1.6 -3.9 b)
Lung 28.5 27.7 28.3 28.5 27.8 28.7 28.9 28.6 28.2 27.7 0.0
Breast 10.7 10.8 12.7 13.9 14.2 14.9 16.1 16.8 17.9 18.7 6.5 b)
Cervix uteri 8.5 7.9 8.3 7.7 7.4 6.8 6.5 6.3 5.7 5.8 -4.6 b)
Corpus uteri 1.4 1.3 1.5 1.7 1.9 1.9 2.0 2.1 2.1 2.4 6.0 b)
Ovary 2.7 2.5 2.5 2.6 2.7 2.7 2.8 2.8 3.0 2.8 1.6 b)
Prostate 3.1 2.7 3.6 3.9 4.8 5.9 6.3 7.2 8.5 9.6 15.2 b)
Testis 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.4 0.4 0.4 3.5 b)
Kidney 3.0 2.9 3.3 3.4 3.5 3.7 4.1 4.4 4.7 5.0 6.4 b)
Bladder 4.6 4.6 4.9 4.7 5.1 5.1 5.1 4.9 4.9 4.7 0.5
Brain and CNS 2.9 2.8 2.8 2.6 2.9 2.9 3.1 2.9 3.1 2.9 1.0 b)
Thyroid 6.3 6.1 7.9 9.5 12.7 17.2 20.6 25.3 32.6 40.8 25.1 b)
Hodgkin lymphoma 0.2 0.3 0.3 0.3 0.3 0.4 0.3 0.3 0.4 0.4 4.5 b)
Non-Hodgkin lymphoma 4.5 4.2 4.5 4.6 4.9 5.2 5.3 5.5 5.5 5.5 3.3 b)
Multiple myeloma 1.0 1.0 1.1 1.1 1.1 1.2 1.3 1.3 1.4 1.4 4.0 b)
Leukemia 4.7 4.3 4.7 4.8 4.7 4.8 4.7 4.9 4.8 5.0 0.9 b)
Other and ill-defined 14.3 13.5 13.9 13.5 15.1 15.1 16.0 15.9 16.8 16.5 -

CNS, central nervous system. a)Annual percent change (APC) using age-standardized incidence based on the World Health Organization (WHO) world standard population, b)The APC is significantly different from zero (p<0.05), c)Includes gallbladder and other/unspecified parts of biliary tract.

Table 6
Trends in cancer incidence rates in males during 1999-2008 in Korea
Sites Year APC a)

1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
All sites 285.0 276.7 288.3 290.0 294.2 298.6 310.4 308.6 314.3 318.5 1.5 b)
Lip, oral cavity, and pharynx 6.1 7.1 6.0 6.2 6.5 6.1 6.0 6.1 6.2 6.4 -0.4
Esophagus 8.8 8.0 8.3 8.2 7.7 7.7 7.6 7.2 6.9 6.9 -2.5 b)
Stomach 66.2 65.0 67.2 66.6 65.9 62.2 66.7 65.2 62.8 63.8 -0.5
Colon and rectum 26.2 27.2 29.6 32.9 35.2 37.8 40.9 43.0 44.8 45.9 7.0 b)
Liver 46.8 44.7 45.1 43.9 42.3 42.1 42.6 40.1 39.5 38.9 -1.9 b)
Gallbladder c) 8.1 7.8 8.2 8.1 7.8 8.4 8.7 8.1 7.9 7.5 -0.2
Pancreas 7.8 7.6 7.6 7.9 7.7 8.0 8.3 8.0 8.2 8.3 0.9 b)
Larynx 4.9 4.5 5.1 4.7 4.4 4.1 4.3 3.7 3.7 3.4 -3.8 b)
Lung 51.4 49.8 51.1 51.0 49.9 50.8 50.8 49.1 48.5 46.9 -0.7 b)
Breast 0.2 0.3 0.2 0.3 0.2 0.2 0.2 0.2 0.1 0.3 -2.2
Prostate 8.4 7.2 9.5 10.1 12.3 15.0 15.7 17.8 20.7 23.0 13.7 b)
Testis 0.6 0.5 0.6 0.6 0.6 0.6 0.6 0.7 0.7 0.7 3.4 b)
Kidney 4.5 4.4 4.9 5.0 5.2 5.5 6.0 6.5 7.0 7.4 6.0 b)
Bladder 9.0 9.0 9.4 9.0 9.7 9.8 9.7 9.5 9.3 9.0 0.3
Brain and CNS 3.2 3.1 3.1 2.9 3.3 3.3 3.4 3.2 3.4 3.3 0.9
Thyroid 2.1 1.9 2.4 2.7 3.7 4.8 5.9 7.5 9.9 13.1 24.5 b)
Hodgkin lymphoma 0.4 0.4 0.4 0.3 0.4 0.5 0.4 0.4 0.5 0.5 2.8
Non-Hodgkin lymphoma 5.8 5.5 5.8 5.8 6.2 6.6 6.4 6.8 6.9 6.7 2.5 b)
Multiple myeloma 1.2 1.3 1.4 1.4 1.4 1.4 1.6 1.4 1.6 1.6 3.1 b)
Leukemia 5.5 5.0 5.4 5.8 5.4 5.7 5.5 5.6 5.6 5.7 0.8
Other and ill-defined 17.9 16.5 16.8 16.5 18.4 18.1 19.1 18.6 19.9 19.1 -

CNS, central nervous system. a)Annual percent change (APC) using age-standardized incidence based on the World Health Organization (WHO) world standard population, b)The APC is significantly different from zero (p<0.05), c)Includes gallbladder and other/unspecified parts of biliary tract

Table 7
Trends in cancer incidence rates in females during 1999-2008 in Korea
Sites Year APC a)

1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
All sites 161.1 157.4 169.0 174.6 183.8 192.8 206.7 215.0 229.7 245.3 5.1 b)
Lip, oral cavity, and pharynx 1.6 2.4 1.7 1.7 1.7 1.8 1.9 1.8 1.9 1.9 0.5
Esophagus 0.6 0.6 0.6 0.5 0.6 0.5 0.4 0.5 0.5 0.5 -2.2 b)
Stomach 26.7 25.2 26.2 26.3 25.9 24.7 26.8 25.0 24.7 24.9 -0.6
Colon and rectum 16.4 16.4 17.9 18.8 20.4 21.4 22.8 23.9 24.2 24.7 5.3 b)
Liver 12.3 11.8 12.2 11.8 11.5 11.3 11.3 11.1 11.0 10.5 -1.5 b)
Gallbladder c) 5.3 5.5 5.7 5.8 5.8 5.9 6.0 5.5 5.6 5.5 0.2
Pancreas 4.0 4.0 4.0 4.2 4.4 4.4 4.7 4.7 4.7 4.8 2.5 b)
Larynx 0.4 0.3 0.3 0.3 0.3 0.3 0.3 0.2 0.2 0.2 -9.0 b)
Lung 12.4 12.5 12.3 12.6 12.4 13.0 13.5 13.9 13.8 13.9 1.5 b)
Breast 20.9 20.9 24.7 27.2 27.8 29.1 31.7 33.1 35.4 36.8 6.7 b)
Cervix uteri 16.3 15.1 15.8 14.8 14.2 13.1 12.4 12.2 11.0 11.2 -4.5 b)
Corpus uteri 2.8 2.6 3.0 3.3 3.8 3.7 3.9 4.0 4.2 4.6 6.2 b)
Ovary 5.0 4.8 4.8 5.0 5.1 5.2 5.4 5.4 5.8 5.5 1.8 b)
Kidney 1.7 1.8 1.9 2.0 2.1 2.2 2.5 2.7 2.8 3.0 6.5 b)
Bladder 1.6 1.6 1.7 1.7 1.8 1.7 1.7 1.6 1.7 1.6 -0.1
Brain and CNS 2.6 2.5 2.5 2.4 2.5 2.7 2.8 2.7 2.8 2.6 1.0
Thyroid 10.4 10.1 13.2 16.2 21.7 29.5 35.2 43.0 55.2 68.6 25.4 b)
Hodgkin lymphoma 0.1 0.2 0.2 0.2 0.2 0.2 0.2 0.3 0.3 0.3 7.1 b)
Non-Hodgkin lymphoma 3.4 3.2 3.4 3.5 3.9 4.1 4.4 4.3 4.3 4.6 4.2 b)
Multiple myeloma 0.8 0.8 0.9 0.8 1.0 1.0 1.2 1.1 1.2 1.2 5.3 b)
Leukemia 3.9 3.8 4.1 4.0 4.1 4.1 4.0 4.3 4.1 4.3 1.1 b)
Other and ill-defined 11.8 11.5 11.8 11.5 12.6 12.9 13.7 13.9 14.4 14.3 -

CNS, central nervous system. a)Annual percent change (APC) using age-standardized incidence based on the World Health Organization (WHO) world standard population, b)The APC is significantly different from zero (p<0.05), c)Includes gallbladder and other/unspecified parts of biliary tract.

Table 8
Five major sites of cancer incidence by age group and sex during 2008 in Korea
Rank Age (yr)

0-14 15-34 35-64 ≥65
Males
1 Leukemia (4.5) Thyroid (8.2) Stomach (92.1) Lung (447.5)
2 Brain and CNS (2.3) Leukemia (3.3) Liver (69.5) Stomach (443.6)
3 Non-Hodgkin lymphoma (1.4) Stomach (2.9) Colon and rectum (64.5) Colon and rectum (323.3)
4 Kidney a) (0.5) Colon and rectum (2.7) Lung (41.4) Prostate (245.3)
5 Testis a) (0.5) Non-Hodgkin lymphoma (2.4) Thyroid (30.0) Liver (211.6)
Females
1 Leukemia (3.7) Thyroid (44.5) Thyroid (166.0) Colon and rectum (161.9)
2 Brain and CNS (1.9) Breast (9.2) Breast (98.8) Stomach (154.0)
3 Non-Hodgkin lymphoma (0.9) Cervix uteri (5.3) Stomach (40.9) Lung (117.7)
4 Thyroid (0.7) Stomach (4.4) Colon and rectum (39.0) Liver (74.5)
5 Ovary (0.7) Ovary (2.7) Cervix uteri (24.2) Thyroid (69.3)

CNS, central nervous system. a)Kidney and testis are same rank.

Table 9
Trends in the 5-yr relative survival rates (%) by year of diagnosis during 1993-2008 in Korea
Sites Total Male Female
1993-1995 1996-2000 2001-2005 2004-2008 Change a) 1993-1995 1996-2000 2001-2005 2004-2008 Change a) 1993-1995 1996-2000 2001-2005 2004-2008 Change a)
All sites 41.2 44.0 53.4 59.5 18.3 31.7 35.3 44.9 50.8 19.1 53.4 55.3 63.5 69.2 15.8
Lip, oral cavity, and pharynx 41.1 46.7 53.7 57.5 16.4 35.8 41.1 48.9 53.1 17.3 58.1 63.8 67.3 69.3 11.2
Esophagus 12.7 15.2 20.7 24.7 12.0 11.8 14.3 20.0 24.0 12.2 23.7 24.2 28.4 32.2 8.5
Stomach 42.8 46.6 57.4 63.1 20.3 43.0 46.9 58.1 63.8 20.8 42.6 46.0 55.9 61.6 19.0
Colon and rectum 54.8 58.0 66.3 70.1 15.3 55.3 59.0 68.3 72.0 16.7 54.2 56.8 63.8 67.5 13.3
Liver 10.7 13.2 19.7 23.3 12.6 9.9 12.9 19.7 23.4 13.5 13.6 14.2 19.7 22.9 9.3
Gallbladder b) 17.3 19.7 22.3 24.9 7.6 16.6 20.3 22.9 25.9 9.3 18.0 19.1 21.7 23.9 5.9
Pancreas 9.4 7.6 7.5 7.6 -1.8 8.8 7.3 7.5 7.3 -1.5 10.1 8.1 7.5 7.9 -2.2
Larynx 59.7 62.3 65.9 69.2 9.5 60.2 62.8 66.5 69.9 9.7 55.4 57.8 57.5 59.1 3.7
Lung 11.3 12.7 15.8 17.5 6.2 10.4 11.6 14.6 15.9 5.5 14.2 16.2 19.1 21.5 7.3
Breast 77.9 83.2 88.2 89.9 12.0 75.1 85.6 86.0 81.5 6.4 78.0 83.2 88.2 90.0 12.0
Cervix uteri 77.5 80.0 81.0 80.5 3.0 - - - 77.5 80.0 81.0 80.5 3.0
Corpus uteri 81.5 81.8 84.5 84.6 3.1 - - - - 81.5 81.8 84.5 84.6 3.1
Ovary 58.7 58.9 61.0 59.9 1.2 - - - - 58.7 58.9 61.0 59.9 1.2
Prostate 55.9 67.2 79.5 86.2 30.3 55.9 67.2 79.5 86.2 30.3 - - - - -
Testis 85.4 90.4 90.4 91.2 5.8 85.4 90.4 90.4 91.2 5.8 - - - - -
Kidney 62.0 66.1 73.2 76.4 14.4 60.8 64.4 72.6 76.4 15.6 64.5 69.7 74.3 76.4 11.9
Bladder 69.1 73.1 75.3 76.1 7.0 70.0 74.8 77.1 77.8 7.8 65.5 66.3 68.1 68.9 3.4
Brain and CNS 38.5 39.0 40.4 42.0 3.5 37.2 37.5 39.7 41.3 4.1 40.2 40.7 41.1 42.7 2.5
Thyroid 94.2 94.9 98.1 99.3 5.1 87.2 89.5 95.6 98.3 11.1 95.4 95.9 98.5 99.5 4.1
Hodgkin lymphoma 68.0 71.2 75.9 80.9 12.9 67.6 68.1 73.9 78.9 11.3 68.6 77.4 80.0 84.7 16.1
Non-Hodgkin lymphoma 46.6 50.8 59.6 62.8 16.2 45.3 48.9 57.7 61.0 15.7 48.7 53.5 62.1 65.0 16.3
Multiple myeloma 22.1 19.8 28.9 33.2 11.1 21.1 17.8 29.1 33.7 12.6 23.3 22.1 28.6 32.8 9.5
Leukemia 26.5 33.3 41.2 44.9 18.4 26.2 32.3 41.1 44.5 18.3 26.8 34.6 41.4 45.4 18.6
Other and ill-defined 42.1 45.9 55.0 60.4 18.3 37.4 42.4 51.4 56.3 18.9 47.4 50.0 59.1 64.9 17.5

CNS, central nervous system. a)Change in the 5-yr relative survival between 1993-1995 and 2004-2008 as a percentage, b)Includes gallbladder and other/unspecified parts of biliary tract.

Table 10
Crude and age-standardized cancer 10-yr prevalent rates on January 1, 2009 by sex during 2008 in Korea
Sites Crude mortality rates/100,000 Age-standardized mortality rates/100,000 a)


Both sexes Male Female Both sexes Male Female
All sites 1,466.8 1,350.4 1,583.7 1,107.4 1,145.0 1,136.2
Lip, oral cavity, and pharynx 22.9 31.2 14.5 17.4 25.8 10.5
Esophagus 10.6 19.1 2.0 8.0 16.4 1.3
Stomach 272.7 362.0 183.0 203.2 302.0 123.6
Colon and rectum 208.5 244.2 172.8 155.1 206.1 115.8
Liver 72.9 109.4 36.3 56.0 90.2 25.9
Gallbladder b) 20.1 20.5 19.7 14.8 17.5 12.9
Pancreas 9.7 10.8 8.6 7.2 9.0 5.8
Larynx 12.9 24.1 1.7 9.7 20.8 1.0
Lung 70.7 94.8 46.5 52.8 81.1 31.2
Breast 160.9 1.5 320.9 118.5 1.3 232.2
Cervix uteri 67.0 - 134.3 49.1 - 95.1
Corpus uteri 18.4 - 36.9 13.9 - 27.2
Ovary 19.7 - 39.5 15.4 - 30.4
Prostate 48.5 96.7 - 34.6 86.3 -
Testis 2.8 5.7 - 2.6 5.2 -
Kidney 30.9 41.5 20.2 23.9 34.2 15.0
Bladder 37.0 60.0 13.9 26.9 51.8 8.6
Brain and CNS 12.7 13.3 12.1 11.6 12.4 10.8
Thyroid 218.0 61.6 375.1 163.1 47.1 277.7
Hodgkin lymphoma 2.5 3.2 1.9 2.2 2.8 1.7
Non-Hodgkin lymphoma 32.7 35.8 29.5 26.1 30.5 22.3
Multiple myeloma 5.0 5.2 4.7 3.8 4.4 3.3
Leukemia 20.1 22.0 18.2 20.0 22.0 18.1
Other and ill-defined 89.7 87.9 91.5 71.1 78.0 65.7

CNS, central nervous system. a)Adjusted to the World Health Organization (WHO) world standard population, b)Includes gallbladder and other/unspecified parts of biliary tract.

Figure & Data

REFERENCES

    Citations

    Citations to this article as recorded by  
    • A Screen-and-Treat Strategy for Eradication of Helicobacter pylori among Patients with Family History of Gastric Cancer in a Diverse US Population
      Mona Zia, Steven Park, Qiaoling Chen, Tiffany Q. Luong, Eva Lustigova, Christie Y. Jeon, Wansu Chen, Bechien U. Wu
      Cancer Epidemiology, Biomarkers & Prevention.2025; 34(2): 340.     CrossRef
    • Prognostic Relationship Between the ABO Blood Groups and Metastatic Gastric Cancer
      Elif Tugba Tuncel, Engin Kut
      Cureus.2023;[Epub]     CrossRef
    • Survival rate of thyroid cancer in the Asian countries: a systematic review and meta-analysis study
      Soheil Hassanipour, Reza Zare, Alireza Shahedi, Hamed Delam
      Endocrine.2023; 82(2): 237.     CrossRef
    • Radiation Enterocolitis Featuring the Perforation of the Sigmoid Colon, Small Bowel, and Entero-Colonic Fistula: A Case Report
      Muzi Meng, Diego Hanssen , Ajit Singh
      Cureus.2023;[Epub]     CrossRef
    • Effect of non-curative endoscopic submucosal dissection on short-term outcomes of subsequent surgery for early gastric cancer
      Feng Zhao, In Cho, Gyu Seok Cho, Jun Chul Chung
      Asian Journal of Surgery.2022; 45(1): 232.     CrossRef
    • Laparotomic radical hysterectomy versus minimally invasive radical hysterectomy using vaginal colpotomy for the management of stage IB1 to IIA2 cervical cancer
      Eun Jung Yang, Nae Ry Kim, A. Jin Lee, Seung-Hyuk Shim, Sun Joo Lee
      Medicine.2022; 101(8): e28911.     CrossRef
    • Health Care Utilization and Anti-Cancer Drug Expenditure for Six Solid Cancers in Korea From 2007 to 2019
      Juhee Park, Kyeongjun Moon, Dong-Sook Kim
      Frontiers in Oncology.2022;[Epub]     CrossRef
    • The Association between Peptic Ulcer Disease and Gastric Cancer: Results from the Stomach Cancer Pooling (StoP) Project Consortium
      Pedram Paragomi, Bashir Dabo, Claudio Pelucchi, Rossella Bonzi, Abdulaziz T. Bako, Nabila Muhammad Sanusi, Quan H. Nguyen, Zuo-Feng Zhang, Domenico Palli, Monica Ferraroni, Khanh Truong Vu, Guo-Pei Yu, Federica Turati, David Zaridze, Dmitry Maximovitch, J
      Cancers.2022; 14(19): 4905.     CrossRef
    • Implications of Radiotherapy Utilization in Korea from 2010 to 2019
      Jeongshim Lee, Woo Chul Kim, Won Sup Yoon, Chai Hong Rim
      Journal of Korean Medical Science.2021;[Epub]     CrossRef
    • Cohort profile: National Investigation of Birth Cohort in Korea study 2008 (NICKs-2008)
      Ju Hee Kim, Jung Eun Lee, So Min Shim, Eun Kyo Ha, Dong Keon Yon, Ok Hyang Kim, Ji Hyeon Baek, Hyun Yong Koh, Kyu Young Chae, Seung Won Lee, Man Yong Han
      Clinical and Experimental Pediatrics.2021; 64(9): 480.     CrossRef
    • Effect of KRAS and BRAF mutations in metastatic colorectal cancer patients: A systematic review and meta-analysis based on tumor sidedness and KRAS subtypes
      Khadijeh Saravani, Morteza Salarzaei, Fateme Parooie
      Human Antibodies.2021; 29(4): 275.     CrossRef
    • Overall survival and prognostic factors prostate cancer in Kurdistan Province-Iran: a population-based study (2011-2018)
      Mohammad Aziz Rasouli, Ghobad Moradi, Bushra Zareie, Heshmatollah Sofimajidpour, Sima Tozandehjani, Hedyeh Zafari, Fatemeh Gholami, Sonia Shahsavari, Parisa Hassani, Mahshid Mohammadian
      BMC Cancer.2021;[Epub]     CrossRef
    • Survival Rate of Prostate Cancer in Asian Countries: A Systematic Review and Meta-Analysis
      Soheil Hassanipour, Hamed Delam, Morteza Arab-Zozani, Elham Abdzadeh, Seyyed Ali Hosseini, Hossein-Ali Nikbakht, Mahdi Malakoutikhah, Mohammad Taghi Ashoobi, Mohammad Fathalipour, Hamid Salehiniya, Shirin Riahi
      Annals of Global Health.2020; 86(1): 2.     CrossRef
    • Laparoscopic Surgery for Colorectal Cancer in Korea: Nationwide Data from 2013 to 2018
      Sun Jin Park, Kil Yeon Lee, Suk-Hwan Lee
      Cancer Research and Treatment.2020; 52(3): 938.     CrossRef
    • Deep Learning in Thyroid Ultrasonography to Predict Tumor Recurrence in Thyroid Cancers
      Jieun Kil, Kwang Gi Kim, Young Jae Kim, Hye Ryoung Koo, Jeong Seon Park
      Journal of the Korean Society of Radiology.2020; 81(5): 1164.     CrossRef
    • Urinary metabolomics for discovering metabolic biomarkers of laryngeal cancer using UPLC-QTOF/MS
      Jian Chen, Hongwei Hou, Huan Chen, Yanbo Luo, Lirong Zhang, Yunfei Zhang, Hansong Liu, Fangfang Zhang, Yong Liu, An Wang, Qingyuan Hu
      Journal of Pharmaceutical and Biomedical Analysis.2019; 167: 83.     CrossRef
    • Complications Following Colonoscopy in a Nationwide Standard Cohort: A Retrospective Case-control Study
      Ji Woo Kim, Su Young Kim, Jung Hye Choi, Hyun-Soo Kim, Jung Kuk Lee, Yun Tae Kim, Geunu Park, Dae Ryong Kang
      The Korean Journal of Gastroenterology.2019; 73(3): 152.     CrossRef
    • High Body Mass Index and Thyroid Stimulating Hormone Levels Do Not Affect Thyroid Nodule Selection for Fine-Needle Aspiration Biopsy after Ultrasound Evaluation
      Hyun Gi Kim, Hye Sun Lee, Eun Kyung Kim, Chung-Mo Nam, Hee Jung Moon, Hae Kyoung Jung, Jin Young Kwak
      International Journal of Thyroidology.2019; 12(1): 44.     CrossRef
    • Performance Evaluation of SENTiFIT 270 and FOB Gold Reagent for Detecting Fecal Occult Blood
      Da Young Kang, Dokyun Kim, Keonhan Kim, In-Ho Jang, Seok Hoon Jeong
      Annals of Clinical Microbiology.2019; 22(2): 29.     CrossRef
    • Study of Gene Expression Profiles of Breast Cancers in Indian Women
      Shreshtha Malvia, Sarangadhara Appala Raju Bagadi, Dibyabhaba Pradhan, Chintamani Chintamani, Amar Bhatnagar, Deepshikha Arora, Ramesh Sarin, Sunita Saxena
      Scientific Reports.2019;[Epub]     CrossRef
    • Potentially modifiable blood triglyceride levels by the control of conventional risk factors
      Bumjo Oh, Joohon Sung, Sohyun Chun
      Lipids in Health and Disease.2019;[Epub]     CrossRef
    • Thirty‐five years of single surgeon experience in the reconstruction of esophagus and voice with free ileocolon flap following total pharyngolaryngectomy
      Hung‐Chi Chen, Pedro Ciudad, Shih‐Heng Chen, Mouchammed Agko
      Journal of Surgical Oncology.2018; 117(3): 459.     CrossRef
    • Molecular Characterization of Urothelial Carcinoma of the Bladder and Upper Urinary Tract
      Ji Yun Lee, Kyung Kim, Hyun Hwan Sung, Hwang Gyun Jeon, Byong Chang Jeong, Seong Il Seo, Seong Soo Jeon, Hyun Moo Lee, Han-Yong Choi, Ghee-Young Kwon, Kyoung-Mee Kim, Jeeyun Lee, Ho Yeong Lim, Se Hoon Park
      Translational Oncology.2018; 11(1): 37.     CrossRef
    • Predicting hypertension among Korean cancer survivors: A nationwide population-based study
      Y.-H. Kim, K.-H. Cho, K.H. Kim, E.J. Ryu, K.D. Han, J.-S. Kim
      European Journal of Cancer Care.2018; 27(2): e12803.     CrossRef
    • A Survey of Radiation Therapy Utilization in Korea from 2010 to 2016: Focusing on Use of Intensity-Modulated Radiation Therapy
      Chai Hong Rim, Jeongshim Lee, Woo Chul Kim, DaeSik Yang, Won Sup Yoon, Woong Sub Koom, Chul Yong Kim
      Journal of Korean Medical Science.2018;[Epub]     CrossRef
    • Instrumentation Failure after Partial Corpectomy with Instrumentation of a Metastatic Spine
      Sung Bae Park, Ki Jeong Kim, Sanghyun Han, Sohee Oh, Chi Heon Kim, Chun Kee Chung
      Journal of Korean Neurosurgical Society.2018; 61(3): 415.     CrossRef
    • l-carnosine induces apoptosis/cell cycle arrest via suppression of NF-κB/STAT1 pathway in HCT116 colorectal cancer cells
      Jooyeon Lee, Jeong-Ran Park, Hanbyeol Lee, Soojin Jang, Se-Min Ryu, Hyejin Kim, Donguk Kim, Aera Jang, Se-Ran Yang
      In Vitro Cellular & Developmental Biology - Animal.2018; 54(7): 505.     CrossRef
    • Cancer in thyroid nodules with fine-needle aspiration in Korean pediatric populations
      Joon Ho Jang, So Hyun Park, Kyung soon Cho, Won Kyung Cho, Young Jin Suh, Byung Kyu Suh, Dae Kyun Koh
      Annals of Pediatric Endocrinology & Metabolism.2018; 23(2): 94.     CrossRef
    • Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma
      Young Saing Kim, Kyung Kim, Ghee-Young Kwon, Su Jin Lee, Se Hoon Park
      BMC Urology.2018;[Epub]     CrossRef
    • Cholecystokinin as a potent diagnostic marker for gastric cancer
      Hafeza Akter, Young Sook Yoo, Won Sang Park, Min-Jung Kang
      BioChip Journal.2017; 11(1): 14.     CrossRef
    • In vivo targeting of c-Met using a non-standard macrocyclic peptide in gastric carcinoma
      Do Won Hwang, Namryeong Bahng, Kenichiro Ito, Seunggyun Ha, Mee Young Kim, Eunji Lee, Hiroaki Suga, Dong Soo Lee
      Cancer Letters.2017; 385: 144.     CrossRef
    • Vulvar cancer in Tunisia: Epidemiological and clinicopathological features multicentric study
      Mehdi Kehila, Souad Harabi, Raoudha Mhiri, Omar Touhami, Hassine Saber Abouda, Abdeljalil Khlifi, Mohamed Hsairi, Dalenda Chelli, Mohamed Derbel, Sahbi Kebaili, Nadia Boujelbane, Kais Chaabene, Mohamed Badis Chanoufi
      Journal of the Egyptian National Cancer Institute.2017; 29(2): 95.     CrossRef
    • Is Endoscopic Resection Really Safe for Mucosal Gastric Cancers?
      Si Hyung Lee
      The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2017; 17(1): 56.     CrossRef
    • Pleural Effusion in Multiple Myeloma: Characteristics and Practice Patterns
      Ja Min Byun, Ki Hwan Kim, In Sil Choi, Jin Hyun Park, Jin-Soo Kim, Dong-Yeop Shin, Youngil Koh, Inho Kim, Sung-Soo Yoon, Hyo Jeong Lim
      Acta Haematologica.2017; 138(2): 69.     CrossRef
    • Assessment of the Risk of Colorectal Cancer Survivors Developing a Second Primary Pancreatic Cancer
      Joo Won Chung, Moon Jae Chung, Seungmin Bang, Seung Woo Park, Si Young Song, Jae Bock Chung, Jeong Youp Park
      Gut and Liver.2017; 11(5): 728.     CrossRef
    • The risk of lymph node metastases in 3951 surgically resected mucosal gastric cancers: implications for endoscopic resection
      Kang Kook Choi, Jae Moon Bae, Su Mi Kim, Tae Sung Sohn, Jae Hyung Noh, Jun Ho Lee, Min-Gew Choi, Sung Kim
      Gastrointestinal Endoscopy.2016; 83(5): 896.     CrossRef
    • Hazard Ratio of Smoking on Lung Cancer in Korea According to Histological Type and Gender
      Young Duk Yun, Joung Hwan Back, Haryeom Ghang, Sun Ha Jee, Yeol Kim, Sun Mi Lee, Jonathan M. Samet, Kang Soo Lee
      Lung.2016; 194(2): 281.     CrossRef
    • Urinary APE1/Ref-1: A Potential Bladder Cancer Biomarker
      Sunga Choi, Ju Hyun Shin, Yu Ran Lee, Hee Kyoung Joo, Ki Hak Song, Yong Gil Na, Seok Jong Chang, Jae Sung Lim, Byeong Hwa Jeon
      Disease Markers.2016; 2016: 1.     CrossRef
    • IMRT vs. 2D-radiotherapy or 3D-conformal radiotherapy of nasopharyngeal carcinoma
      Sung Ho Moon, Kwan Ho Cho, Chang-Geol Lee, Ki Chang Keum, Yeon-Sil Kim, Hong-Gyun Wu, Jin Ho Kim, Yong Chan Ahn, Dongryul Oh, Jong Hoon Lee
      Strahlentherapie und Onkologie.2016; 192(6): 377.     CrossRef
    • Surgical management of extra-regional lymph node metastasis in colorectal cancer
      Mahdi H. Albandar, Min Soo Cho, Sung Uk Bae, Nam Kyu Kim
      Expert Review of Anticancer Therapy.2016; 16(5): 503.     CrossRef
    • Altered Secretory Activity of APE1/Ref-1 D148E Variants Identified in Human Patients With Bladder Cancer
      Yu Ran Lee, Jae Sung Lim, Ju Hyun Shin, Sunga Choi, Hee Kyoung Joo, Byeong Hwa Jeon
      International Neurourology Journal.2016; 20(Suppl 1): S30.     CrossRef
    • Laparoscopic gastric cancer surgery: Current evidence and future perspectives
      Taeil Son
      World Journal of Gastroenterology.2016; 22(2): 727.     CrossRef
    • Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02)
      Ji Yun Lee, Xu Qing, Wei Xiumin, Bai Yali, Sangah Chi, So Hyeon Bak, Ho Yun Lee, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Eun Kyung Cho, Dong-Wan Kim, Hye Ryun Kim, Young Joo Min, Sin-Ho Jung, Keunchil Park, Mao Mao, Myung-Ju Ahn
      Oncotarget.2016; 7(6): 6984.     CrossRef
    • A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non–Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib
      Ji Yun Lee, Jong-Mu Sun, Sung Hee Lim, Hae Su Kim, Kwai Han Yoo, Ki Sun Jung, Haa-Na Song, Bo Mi Ku, Jiae Koh, Yeon-Hee Bae, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn
      Clinical Cancer Research.2016; 22(9): 2139.     CrossRef
    • Personalized Surgery for Gastric Adenocarcinoma: A Meta-analysis of D1 versus D2 Lymphadenectomy
      Abraham El-Sedfy, Matthew Dixon, Rajini Seevaratnam, Alina Bocicariu, Roberta Cardoso, Alyson Mahar, Alex Kiss, Lucy Helyer, Calvin Law, Natalie G. Coburn
      Annals of Surgical Oncology.2015; 22(6): 1820.     CrossRef
    • Clinical significance of skip lymph node metastasis in gastric cancer patients
      D.H. Kim, M.G. Choi, J.H. Noh, T.S. Sohn, J.M. Bae, S. Kim
      European Journal of Surgical Oncology (EJSO).2015; 41(3): 339.     CrossRef
    • X-Ray-based Kinematic Analysis of Cervical Spine According to Prosthesis Designs
      Sung B. Park, Ki J. Kim, Yong J. Jin, Hyun J. Kim, Tae-A. Jahng, Chun K. Chung
      Journal of Spinal Disorders & Techniques.2015; 28(5): E291.     CrossRef
    • APE1/Ref-1 as a Serological Biomarker for the Detection of Bladder Cancer
      Ju Hyun Shin, Sunga Choi, Yu Ran Lee, Myoung Soo Park, Yong Gil Na, Kaikobad Irani, Sang Do Lee, Jin Bong Park, Jin Man Kim, Jae Sung Lim, Byeong Hwa Jeon
      Cancer Research and Treatment.2015; 47(4): 823.     CrossRef
    • The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non–Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors
      Ji Yun Lee, Bo Mi Ku, Sung Hee Lim, Min-Young Lee, Haesu Kim, Moonjin Kim, Sungmin Kim, Hyun Ae Jung, Jong-Mu Sun, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn
      Journal of Thoracic Oncology.2015; 10(6): 903.     CrossRef
    • Incidence of kidney, bladder, and prostate cancers in Korea: An update
      Wan Song, Hwang Gyun Jeon
      Korean Journal of Urology.2015; 56(6): 422.     CrossRef
    • Computational Discrimination of Breast Cancer for Korean Women Based on Epidemiologic Data Only
      Chiwon Lee, Jung Chan Lee, Boyoung Park, Jonghee Bae, Min Hyuk Lim, Daehee Kang, Keun-Young Yoo, Sue K. Park, Youdan Kim, Sungwan Kim
      Journal of Korean Medical Science.2015; 30(8): 1025.     CrossRef
    • Gene-gene interaction analysis identifies a new genetic risk factor for colorectal cancer
      Jongkeun Park, Injung Kim, Keum Ji Jung, Soriul Kim, Sun Ha Jee, Sungjoo Kim Yoon
      Journal of Biomedical Science.2015;[Epub]     CrossRef
    • Reflex Human Papillomavirus Test Results as an Option for the Management of Korean Women With Atypical Squamous Cells Cannot Exclude High-Grade Squamous Intraepithelial Lesion
      Ki-Jin Ryu, Sanghoon Lee, Kyung-Jin Min, Jae Won Kim, Jin Hwa Hong, Jae Yun Song, Jae Kwan Lee, Nak Woo Lee
      The Oncologist.2015; 20(6): 635.     CrossRef
    • Prognosis of Prostate Cancer With Other Primary Malignancies
      Ju Hyun Lim, Dalsan You, In Gab Jeong, Jun Hyuk Hong, Hanjong Ahn, Choung-Soo Kim
      Korean Journal of Urology.2014; 55(5): 327.     CrossRef
    • Lung cancer risk among patients with combined pulmonary fibrosis and emphysema
      Nakwon Kwak, Chang-Min Park, Jinwoo Lee, Young Sik Park, Sang-Min Lee, Jae-Joon Yim, Chul-Gyu Yoo, Young Whan Kim, Sung Koo Han, Chang-Hoon Lee
      Respiratory Medicine.2014; 108(3): 524.     CrossRef
    • Efficacy of concurrent chemoradiotherapy with 5-fluorouracil or gemcitabine in locally advanced biliary tract cancer
      Seung Woo Yi, Dae Ryong Kang, Kyung Sik Kim, Mi Suk Park, Jinsil Seong, Jeong Youp Park, Seung Min Bang, Si Young Song, Jae Bock Chung, Seung Woo Park
      Cancer Chemotherapy and Pharmacology.2014; 73(1): 191.     CrossRef
    • Preclinical Efficacy Testing for Stomach and Liver Cancers
      Jun Won Park, Nam Suk Baek, Seok Cheol Lee, Su Jin Oh, Seok Hoon Jang, In Hoo Kim, Dae Yong Kim, Hark Kyun Kim
      Cancer Research and Treatment.2014; 46(2): 186.     CrossRef
    • The availability of computed tomography for pulmonary staging in colorectal cancer
      Bo-Young Oh, Gyoung Tae Noh, Kyung Sook Hong, Soon Sup Chung, Kwang Ho Kim, Ryung-Ah Lee
      Annals of Surgical Treatment and Research.2014; 86(4): 212.     CrossRef
    • Ischemic Stroke in Patients with Cancer: Is it Different from Usual Strokes?
      Eun-Jae Lee, Hyun-Wook Nah, Joo-Young Kwon, Dong-Wha Kang, Sun U. Kwon, Jong S. Kim
      International Journal of Stroke.2014; 9(4): 406.     CrossRef
    • Burden of disease in Korea during 2000-10
      K. S. Lee, J. H. Park
      Journal of Public Health.2014; 36(2): 225.     CrossRef
    • Gray-Scale Ultrasonography Combined with Elastography Imaging for the Evaluation of Papillary Thyroid Microcarcinoma: As a Prognostic Clinicopathology Factor
      Zhan-Qiang Jin, Mei-Ying Lin, Wen-Hua Hu, Wei-Yong Li, Shao-Jun Bai
      Ultrasound in Medicine & Biology.2014; 40(8): 1769.     CrossRef
    • Attributable fraction of alcohol consumption on cancer using population-based nationwide cancer incidence and mortality data in the Republic of Korea
      Sohee Park, Hai-Rim Shin, Boram Lee, Aesun Shin, Kyu-Won Jung, Duk-Hee Lee, Sun Ha Jee, Sung-Il Cho, Sue Kyung Park, Mathieu Boniol, Paolo Boffetta, Elisabete Weiderpass
      BMC Cancer.2014;[Epub]     CrossRef
    • Low C24‐OH and C22‐OH sulfatides in human renal cell carcinoma
      Il Chan Kim, Geul Bang, Jeong Hwa Lee, Kwang Pyo Kim, Young Hwan Kim, Hark Kyun Kim, Jinsoo Chung
      Journal of Mass Spectrometry.2014; 49(5): 409.     CrossRef
    • Modified MVAC as a Second-Line Treatment for Patients with Metastatic Urothelial Carcinoma after Failure of Gemcitabine and Cisplatin Treatment
      Jung Hyun Lee, Sung Gu Kang, Seung Tae Kim, Seok Ho Kang, In Keun Choi, Young Je Park, Sang Chul Oh, Deuk Jae Sung, Jae Hong Seo, Jun Cheon, Sang Won Shin, Yeul Hong Kim, Jun Suk Kim, Kyong Hwa Park
      Cancer Research and Treatment.2014; 46(2): 172.     CrossRef
    • Toxicity and quality of life of Korean breast cancer patients treated with docetaxel-containing chemotherapy without primary G-CSF prophylaxis
      Jihyoun Lee, Min Hye Ahn, Yun Hee Jang, Eun Ju Lee, Ji Hye Park, Jungho Rho, Zisun Kim, Hyuk Mun Kim, Sun Wook Han, Cheolwan Lim, Min Hyuk Lee, Sung Yong Kim
      Breast Cancer.2014; 21(6): 670.     CrossRef
    • Comprehension of readmission after laparoscopy assisted distal gastrectomy: what are the causes?
      Min-Chan Kim, Ki-Han Kim, Yoo-Min Kim, Ghap-Joong Jung
      Annals of Surgical Treatment and Research.2014; 86(5): 237.     CrossRef
    • Prognostic Impact of Microscopic Tumor Involved Resection Margin in Advanced Gastric Cancer Patients after Gastric Resection
      Jung‐Woo Woo, Keun Won Ryu, Ji Yeon Park, Bang Wool Eom, Mi Jung Kim, Hong Man Yoon, Sook Ryun Park, Myeong‐Cherl Kook, Il Ju Choi, Young‐Woo Kim, Young‐Iee Park
      World Journal of Surgery.2014; 38(2): 439.     CrossRef
    • Bone mineral density and the risk of breast cancer: a case-control study of Korean women
      Bo-Kyoung Kim, Yoon-Ho Choi, Yun-Mi Song, Joo-Hyun Park, Hye-Mi Noh, Tuong L. Nguyen, John L. Hopper
      Annals of Epidemiology.2014; 24(3): 222.     CrossRef
    • Different methylation profiles between intestinal and diffuse sporadic gastric carcinogenesis
      Misuk Yang, Hyun-Soo Kim, Mee Yon Cho
      Clinics and Research in Hepatology and Gastroenterology.2014; 38(5): 613.     CrossRef
    • Do newly built homes affect rhinitis in children? The ISAAC phase III study in Korea
      M.‐I. Hahm, Y. Chae, H.‐J. Kwon, J. Kim, K. Ahn, W.‐K. Kim, S.‐Y. Lee, Y. M. Park, M. Y. Han, K.‐J. Lee, H.‐Y. Lee, I. Min
      Allergy.2014; 69(4): 479.     CrossRef
    • Influenza Vaccination and Associated Factors among Korean Cancer Survivors : A Cross-Sectional Analysis of the Fourth & Fifth Korea National Health and Nutrition Examination Surveys
      Kyung-Hyun Choi, Sang Min Park, Kiheon Lee, Ju Hyun Lee, Joo-Sung Park
      Journal of Korean Medical Science.2014; 29(8): 1061.     CrossRef
    • Clinical Characteristics of Long-Term Survivors of Inoperable Pancreatic Cancer
      Jung Hyun Jo, Moon Jae Chung, Jeong Youp Park, Seungmin Bang, Seung Woo Park, Jae Bock Chung, Si Young Song
      Pancreas.2014; 43(7): 1022.     CrossRef
    • Association of ATM Gene Polymorphism with PTC Metastasis in Female Patients
      Yulu Gu, Xiaoli Liu, Yaqin Yu, Jieping Shi, Lizhe Ai, Hui Sun, Joseph Sam Kanu, Chong Wang, Yawen Liu
      International Journal of Endocrinology.2014; 2014: 1.     CrossRef
    • Colon Cancer Screening with Image-Enhanced Endoscopy
      Bong Min Ko
      Clinical Endoscopy.2014; 47(6): 504.     CrossRef
    • Risk Factors for Distant Metastasis as a Primary Site of Treatment Failure in Early-Stage Breast Cancer
      Hyeli Park, Sei Kyung Chang, Ja Young Kim, Bo Mi Lee, Hyun Soo Shin
      Chonnam Medical Journal.2014; 50(3): 96.     CrossRef
    • Anti-tumor efficacy of fulvestrant in estrogen receptor positive gastric cancer
      Jun Ho Yi, In-Gu Do, Jiryeon Jang, Seung Tae Kim, Kyoung-Mee Kim, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang, Jeeyun Lee
      Scientific Reports.2014;[Epub]     CrossRef
    • Incidence of Primary Spinal Cord, Spinal Meninges, and Cauda Equina Tumors in Korea, 2006-2010
      Kyu-Won Jung, Kwang Hyon Park, Johyun Ha, Seung Hoon Lee, Young-Joo Won, Heon Yoo
      Cancer Research and Treatment.2014; 47(2): 166.     CrossRef
    • Endogenous Nitric Oxide Strengthens Doxorubicin-induced Apoptosis in Human Colorectal Cell Lines
      Soon Jae Im, Ji Hye Kim, Min Young Kim
      Journal of Life Science.2014; 24(10): 1137.     CrossRef
    • Relationship between Perceived Spouse Support and Health Promoting Behavior in the Breast Cancer Patient with Mastectomy
      Young Mi Kim, Hyoung Sook Park
      Asian Oncology Nursing.2014; 14(4): 203.     CrossRef
    • Combined Effects of Smoking and Bilirubin Levels on the Risk of Lung Cancer in Korea: The Severance Cohort Study
      Jung-eun Lim, Heejin Kimm, Sun Ha Jee, Suminori Akiba
      PLoS ONE.2014; 9(8): e103972.     CrossRef
    • Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of HER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study
      Taroh Satoh, Rui-Hua Xu, Hyun Cheol Chung, Guo-Ping Sun, Toshihiko Doi, Jian-Ming Xu, Akihito Tsuji, Yasushi Omuro, Jin Li, Jin-Wan Wang, Hiroto Miwa, Shu-Kui Qin, Ik-Joo Chung, Kun-Huei Yeh, Ji-Feng Feng, Akihira Mukaiyama, Mikiro Kobayashi, Atsushi Ohts
      Journal of Clinical Oncology.2014; 32(19): 2039.     CrossRef
    • Clinicopathologic Significance of Nuclear Factor-κB and Vascular Endothelial Growth Factor Expression in Advanced Gastric Cancer Patients
      Keon Woo Park, Su-Jin Kim, Sung Yong Oh
      Oncology Research and Treatment.2014; 37(4): 183.     CrossRef
    • Prevalence and Risk Factors of Colorectal Adenoma in 14,932 Koreans Undergoing Screening Colonoscopy
      Hee Sun Kim, Su Jung Baik, Kyung Hee Kim, Cho Rong Oh, Sang In Lee
      The Korean Journal of Gastroenterology.2013; 62(2): 104.     CrossRef
    • Health Behaviors of Cancer Survivors: The Fourth Korea National Health and Nutrition Examination Survey (KNHANES IV, 2007-09)
      M. G. Oh, M. A. Han, J. Park, S. Y. Ryu, C.-Y. Park, S. W. Choi
      Japanese Journal of Clinical Oncology.2013; 43(10): 981.     CrossRef
    • Clinical Features and Prognostic Factors in Elderly Koreans with Advanced Non-Small-Cell Lung Cancer in a Tertiary Referral Hospital
      Seo Woo Kim, Mi Yeon Kim, Yoon Pyo Lee, Yon Ju Ryu, Seok Jeong Lee, Jin Hwa Lee, Jung Hyun Chang, Sung Shine Shim
      Tuberculosis and Respiratory Diseases.2013; 75(2): 52.     CrossRef
    • Disability Weights for Cancers in Korea
      Kyu Sik Choi, Jae Hyun Park, Kwang Sig Lee
      Journal of Korean Medical Science.2013; 28(6): 808.     CrossRef
    • Expression of Multidrug Resistance-Associated Protein 2 in Human Gallbladder Carcinoma
      Hyun-Soo Kim, Nam Chul Kim, Kyu Hee Chae, Gun Kim, Won Seo Park, Yong-Koo Park, Youn Wha Kim
      BioMed Research International.2013; 2013: 1.     CrossRef
    • Sex-specific differences in the association between ABO genotype and gastric cancer risk in a Korean population
      Hye-Rim Song, Min-Ho Shin, Hee Nam Kim, Jin-Mei Piao, Jin-Su Choi, Jun-Eul Hwang, Young-Kyu Park, Dong-Wook Ryang, Duck Cho, Sun-Seog Kweon
      Gastric Cancer.2013; 16(2): 254.     CrossRef
    • Expression of Heat Shock Protein 70 Modulates the Chemoresponsiveness of Pancreatic Cancer
      Jong Jin Hyun, Hong Sik Lee, Bora Keum, Yeon Seok Seo, Yoon Tae Jeen, Hoon Jai Chun, Soon Ho Um, Chang Duck Kim
      Gut and Liver.2013; 7(6): 739.     CrossRef
    • Hormonal Therapy for Women With Stage IA Endometrial Cancer of All Grades
      Jeong-Yeol Park, Dae-Yeon Kim, Tae-Jin Kim, Jae Weon Kim, Jong-Hyeok Kim, Yong-Man Kim, Young-Tak Kim, Duk-Soo Bae, Joo-Hyun Nam
      Obstetrics & Gynecology.2013; 122(1): 7.     CrossRef
    • DHPLC is a highly sensitive and rapid screening method to detect BRAFV600E mutation in papillary thyroid carcinoma
      Tae Eun Kim, Eun Sun Jung, Chan Kwon Jung, Ja Seong Bae, Seung Nam Kim, Gyeong Suk Kim, Hyoung Nam Lee, Chang Suk Kang, Yeong Jin Choi
      Experimental and Molecular Pathology.2013; 94(1): 203.     CrossRef
    • Connexin32 inhibits gastric carcinogenesis through cell cycle arrest and altered expression of p21Cip1 and p27Kip1
      Hyang Jee, Su-Hyung Lee, Jun-Won Park, Bo-Ram Lee, Ki-Taek Nam, Dae-Yong Kim
      BMB Reports .2013; 46(1): 25.     CrossRef
    • Outcomes of Laparoscopic Gastrectomy after Endoscopic Treatment for Gastric Cancer: A Comparison with Open Gastrectomy
      Hye Youn Kwon, Woo Jin Hyung, Joong Ho Lee, Sang Kil Lee, Sung Hoon Noh
      Journal of Gastric Cancer.2013; 13(1): 51.     CrossRef
    • Optimal Time of Initiating Adjuvant Chemotherapy After Curative Surgery in Colorectal Cancer Patients
      Kyu Min Kang, Kyung Sook Hong, Gyoung Tae Noh, Bo-Young Oh, Soon Sup Chung, Ryung-Ah Lee, Kwang Ho Kim
      Annals of Coloproctology.2013; 29(4): 150.     CrossRef
    • A Multicenter Retrospective Analysis of the Clinical Features of Pernicious Anemia in a Korean Population
      Ik-Chan Song, Hyo Jin Lee, Han-Jo Kim, Sang-Byung Bae, Kyu-Taek Lee, Young-Jun Yang, Suk-Young Park, Do-Yeun Cho, Nae Yu Kim, In-Sung Cho, Deog-Yeon Jo
      Journal of Korean Medical Science.2013; 28(2): 200.     CrossRef
    • Transglutaminase 2 Expression Predicts Progression Free Survival in Non-Small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
      Jae-Heon Jeong, Byoung Chul Cho, Hyo Sup Shim, Hye-Ryun Kim, Sun-Min Lim, Se Kyu Kim, Kyung Young Chung, S.M. Bakhtiar Ul Islam, Jae Jin Song, Soo-Youl Kim, Joo Hang Kim
      Journal of Korean Medical Science.2013; 28(7): 1005.     CrossRef
    • Prevalence of the Metabolic Syndrome and Associated Factors in Korean Cancer Survivors
      Jung-Yun Lee, Noh Hyun Park, Yong-Sang Song, Sang Min Park, Hae-Won Lee, Kyae Hyung Kim, Kyung-Hyun Choi
      Asian Pacific Journal of Cancer Prevention.2013; 14(3): 1773.     CrossRef
    • Clinical significance of microscopic anaplastic focus in papillary thyroid carcinoma
      June Young Choi, Bo Hyun Hwang, Kyeong Cheon Jung, Hye Sook Min, Do Hoon Koo, Yeo-Kyu Youn, Kyu Eun Lee
      Surgery.2013; 154(1): 106.     CrossRef
    • Predicting Survival in Patients with Advanced Non-squamous Non-small Cell Lung Cancer: Validating the Extent of Metastasis
      Dong Soo Lee, Jin Hyoung Kang, Chang Geol Lee, Seoung Jun Kim, Young Jin Choi, Kyo Young Lee, Yeon Sil Kim
      Cancer Research and Treatment.2013; 45(2): 95.     CrossRef
    • Laparoscopic versus open radical hysterectomy in patients with stage IB2 and IIA2 cervical cancer
      Jeong‐Yeol Park, Dae‐Yeon Kim, Jong‐Hyeok Kim, Yong‐Man Kim, Young‐Tak Kim, Joo‐Hyun Nam
      Journal of Surgical Oncology.2013; 108(1): 63.     CrossRef
    • The application of PET-CT to post-mastectomy regional radiation therapy using a deformable image registration
      Yu Sun Lee, Kyoung Ju Kim, Seung Do Ahn, Eun Kyung Choi, Jong Hoon Kim, Sang-wook Lee, Si Yeol Song, Sang Min Yoon, Young Seok Kim, Jin-hong Park, Byung Chul Cho, Su Ssan Kim
      Radiation Oncology.2013;[Epub]     CrossRef
    • Clinical manifestation of cancer related stroke: retrospective case–control study
      Jeong-Min Kim, Keun-Hwa Jung, Kee Hong Park, Soon-Tae Lee, Kon Chu, Jae-Kyu Roh
      Journal of Neuro-Oncology.2013; 111(3): 295.     CrossRef
    • Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival
      Eun Joo Kang, Seock-Ah Im, Do-Youn Oh, Sae-Won Han, Jin-Soo Kim, In Sil Choi, Jin Won Kim, Yu Jung Kim, Jee Hyun Kim, Tae-You Kim, Jong Seok Lee, Yung-Jue Bang, Keun-Wook Lee
      Gastric Cancer.2013; 16(4): 581.     CrossRef
    • Commentary: the association between low-dose aspirin use and the incidence of colorectal cancer
      N. Burr, M. A. Hull
      Alimentary Pharmacology & Therapeutics.2013; 38(6): 653.     CrossRef
    • The Status for Radiation Treatment of Cancer Patients focused on Busan Area
      Euntae Park, Sungkwang Park
      Journal of the Korean Society of Radiology.2013; 7(2): 151.     CrossRef
    • The relationship of Vascular endothelial growth factor gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX: VEGF polymorphism in gastric cancer
      Sung Yong Oh, Hyuk-Chan Kwon, Sung Hyun Kim, Suee Lee, Ji Hyun Lee, Jung-Ah Hwang, Seung Hyun Hong, Christian A Graves, Kevin Camphausen, Hyo-Jin Kim, Yeon-Su Lee
      BMC Cancer.2013;[Epub]     CrossRef
    • Diagnostic Accuracy of the Ultrasonographic Features for Subcentimeter Thyroid Nodules Suggested by the Revised American Thyroid Association Guidelines
      Hyun Gi Kim, Hee-Jung Moon, Jin Young Kwak, Eun-Kyung Kim
      Thyroid.2013; 23(12): 1583.     CrossRef
    • A Case of Atypical Adenomatous Hyperplasia of Larger Than 2 cm
      Bo Mi Park, Min Ji Cho, Hyun Seok Lee, Dong Il Park, Myoung Rin Park, Ju Ock Kim, Jeong Eun Lee, Choong Sik Lee, Sung Soo Jung
      Tuberculosis and Respiratory Diseases.2013; 74(6): 280.     CrossRef
    • Global estimates of cancer prevalence for 27 sites in the adult population in 2008
      Freddie Bray, Jian‐Song Ren, Eric Masuyer, Jacques Ferlay
      International Journal of Cancer.2013; 132(5): 1133.     CrossRef
    • Association of the miR‐146aC>G, miR‐149T>C, miR‐196a2T>C, and miR‐499A>G polymorphisms with gastric cancer risk and survival in the korean population
      Dae Ho Ahn, HyungChul Rah, Young‐Kook Choi, Young Joo Jeon, Kyung Tae Min, KyuBum Kwack, Sung Pyo Hong, Seong Gyu Hwang, Nam Keun Kim
      Molecular Carcinogenesis.2013; 52(S1): 39.     CrossRef
    • Nutritional Assessment and Perioperative Nutritional Support in Gastric Cancer Patients
      Kyung Won Seo, Ki Young Yoon
      The Korean Journal of Gastroenterology.2013; 61(4): 186.     CrossRef
    • Ground-Glass Opacity in Lung Metastasis from Breast Cancer: A Case Report
      Sae Byol Kim, Soohyeon Lee, Myoung Ju Koh, In Seon Lee, Chan Soo Moon, Sung Mo Jung, Young Ae Kang
      Tuberculosis and Respiratory Diseases.2013; 74(1): 32.     CrossRef
    • Prognostic Significance of Serum Carcinoembryonic Antigen Normalization on Survival in Rectal Cancer Treated with Preoperative Chemoradiation
      Mi-Joo Chung, Su-Mi Chung, Ji-Yoon Kim, Mi-Ryeong Ryu
      Cancer Research and Treatment.2013; 45(3): 186.     CrossRef
    • Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy
      Suee Lee, Sung Yong Oh, Sung Hyun Kim, Ji Hyun Lee, Min Chan Kim, Ki Han Kim, Hyo-Jin Kim
      BMC Cancer.2013;[Epub]     CrossRef
    • Clinical Significance and Long-Term Outcome of Incidentally Found Bile Duct Dilatation
      Jaryong Jeon, Song Yi Song, Kyu Taek Lee, Kwang Hyuck Lee, Mun Hee Bae, Jong Kyun Lee
      Digestive Diseases and Sciences.2013; 58(11): 3293.     CrossRef
    • Hazard of Recurrence after Breast Surgery according to Hormone Receptor Status and Age
      Seung Pil Jung, Sook-young Woo, Se Kyung Lee, Sangmin Kim, Soo Youn Bae, Jiyoung Kim, Min Kuk Kim, Won Ho Kil, Seok Jin Nam, Jeong Eon Lee
      Journal of Breast Disease.2013; 1(1): 15.     CrossRef
    • Antiadhesive effect and safety of oxidized regenerated cellulose after thyroidectomy: a prospective, randomized controlled study
      Kyoung Sik Park, Kyu Eun Lee, Do Hoon Ku, Su-Jin Kim, Won Seo Park, Hoon Yub Kim, Mi Ra Kwon, Yeo-Kyu Youn
      Journal of the Korean Surgical Society.2013; 84(6): 321.     CrossRef
    • The Iatrogenic Complications of Colonoscopic Polypectomy: A Multicenter Retrospective Study
      Min Ho Choi, Yun Sun Choi, Chan Soo So, Woon Geon Shin, Kyoung Oh Kim, Hyun Joo Jang, Cheol Hee Park, Kyung Ho Kim, Jin Bae Kim, Il Hyun Baek, Kwang Ho Baik, Sea Hyub Kae, Hak Yang Kim
      Intestinal Research.2013; 11(1): 46.     CrossRef
    • Prioritization of Research Topics of Korean Oncology Nurses
      Eun-Hyun Lee, Bok Yae Chung, Nami Chun, Pok Ja Oh, Soo-Yeon Cho
      Asian Oncology Nursing.2013; 13(4): 295.     CrossRef
    • Subunit-specific mass spectrometry method identifies haptoglobin subunit alpha as a diagnostic marker in non-small cell lung cancer
      Jisook Park, Jeong Soo Yang, Gyuyon Jung, Hye In Woo, Hyung-Doo Park, Jong-Won Kim, Wooseong Huh, Jae-Wook Ko, Hojoong Kim, Je-Yoel Cho, Soo-Youn Lee
      Journal of Proteomics.2013; 94: 302.     CrossRef
    • Method of Reconstruction Governs Iron Metabolism After Gastrectomy for Patients With Gastric Cancer
      Joong Ho Lee, Woo Jin Hyung, Hyoung-Il Kim, Yoo-Min Kim, Taeil Son, Naoki Okumura, Yanfeng Hu, Choong-Bai Kim, Sung Hoon Noh
      Annals of Surgery.2013; 258(6): 964.     CrossRef
    • Prevalence of and Factors Associated with Osteoporosis among Korean Cancer Survivors: A Cross-Sectional Analysis of the Fourth and Fifth Korea National Health and Nutrition Examination Surveys
      Kyung-Hyun Choi, Sang Min Park, Joo-Sung Park, Jae-Hyun Park, Kyae Hyung Kim, Myung-Ju Kim
      Asian Pacific Journal of Cancer Prevention.2013; 14(8): 4743.     CrossRef
    • Burden of cancer in Korea during 2000–2020
      Jae-Hyun Park, Kwang-Sig Lee, Kyu-Sik Choi
      Cancer Epidemiology.2013; 37(4): 353.     CrossRef
    • Clinical outcome with gamma-knife surgery or surgery for brain metastases from colorectal cancer
      Hun Jin Kim, Jung Wook Huh, Tae Young Jung, In Young Kim, Hyeong Rok Kim, Shin Jung, Young Jin Kim
      Journal of Clinical Neuroscience.2013; 20(10): 1417.     CrossRef
    • Lateral Topography for Reducing Effective Dose in Low-Dose Chest CT
      Dong-Ho Bang, Daekeon Lim, Wi-Sub Hwang, Seong-Hoon Park, Ok-man Jeong, Kyung Wook Kang, Hohyung Kang
      American Journal of Roentgenology.2013; 200(6): 1294.     CrossRef
    • Validation of a Web-Based Tool to Predict the Ipsilateral Breast Tumor Recurrence (IBTR! 2.0) after Breast-Conserving Therapy for Korean Patients
      Seung Pil Jung, Sung Mo Hur, Se Kyung Lee, Sangmin Kim, Min-Young Choi, Soo Youn Bae, Jiyoung Kim, Min Kuk Kim, Won Ho Kil, Jun-Ho Choe, Jung-Han Kim, Jee Soo Kim, Seok Jin Nam, Jeoung Won Bae, Jeong Eon Lee
      Journal of Breast Cancer.2013; 16(1): 97.     CrossRef
    • Body Mass Index as a Predictor of Advanced Colorectal Neoplasia
      Hyuk Jin Kwon, Hee Jin Kim, Young Soo Park, Ji Hyun Lim, Kyoung Jun Park, Cheol Min Shin, Jin-Hyeok Hwang, Jin-Wook Kim, Sook-Hyang Jeong, Nayoung Kim, Dong Ho Lee
      Journal of Cancer Prevention.2013; 18(2): 144.     CrossRef
    • A Multidisciplinary Approach to the Treatment of Gastric Cancer: What Is the Role of the Surgeon?
      Abraham El-Sedfy, Fadi Frankul, Natalie G. Coburn
      Journal of Cancer Therapy.2013; 04(09): 16.     CrossRef
    • Prevalence, Awareness, Control, and Treatment of Hypertension and Diabetes in Korean Cancer Survivors: A Cross-Sectional Analysis of the Fourth and Fifth Korea National Health and Nutrition Examination Surveys
      Kyung-Hyun Choi, Sang Min Park, Kiheon Lee, Kyae Hyung Kim, Joo-Sung Park, Seong Ho Han
      Asian Pacific Journal of Cancer Prevention.2013; 14(12): 7685.     CrossRef
    • Validity of Fecal Occult Blood Test in the National Cancer Screening Program, Korea
      Aesun Shin, Kui Son Choi, Jae Kwan Jun, Dai Keun Noh, Mina Suh, Kyu-Won Jung, Byung Chang Kim, Jae Hwan Oh, Eun-Cheol Park, John Souglakos
      PLoS ONE.2013; 8(11): e79292.     CrossRef
    • Effects of matrine on the proliferation of HT29 human colon cancer cells and its antitumor mechanism
      CHENG CHANG, SHAO-PING LIU, CHUN-HUA FANG, REN-SHENG HE, ZHEN WANG, YOU-QING ZHU, SHAO-WEI JIANG
      Oncology Letters.2013; 6(3): 699.     CrossRef
    • Fertility-Sparing Surgery for Young Women with Early-Stage Epithelial Ovarian Cancer
      Joo-Hyun Nam, Jeong-Yeol Park
      Gynecologic and Obstetric Investigation.2013; 76(1): 14.     CrossRef
    • Efficacy and feasibility of gemcitabine and carboplatin as first-line chemotherapy in elderly patients with advanced non-small cell lung cancer
      Kyu-Hyoung Lim, Hui-Young Lee, Seo-Young Song
      Chinese Medical Journal.2013; 126(24): 4644.     CrossRef
    • Korean Guidelines for Colorectal Cancer Screening and Polyp Detection
      Bo In Lee, Sung Pil Hong, Seong-Eun Kim, Se Hyung Kim, Hyun-Soo Kim, Sung Noh Hong, Dong-Hoon Yang, Sung Jae Shin, Suck-Ho Lee, Young-Ho Kim, Dong Il Park, Hyun Jung Kim, Suk-Kyun Yang, Hyo Jong Kim, Hae Jeong Jeon
      Intestinal Research.2012; 10(1): 67.     CrossRef
    • Plasma human mammaglobin mRNA associated with poor outcome in patients with breast cancer
      G.-W. Lee, J.-Y. Kim, E.-H. Koh, D. Kang, D.S. Choi, K.-Y. Maeng, J.-S. Lee
      Genetics and Molecular Research.2012; 11(4): 4034.     CrossRef
    • RASSF1A and ERCC1 Expression Levels Might Be Predictive of Prognosis in Advanced, Recurrent, and Metastatic Squamous Cell Carcinoma of the Head and Neck Treated with Docetaxel and Cisplatin
      Yong Park, Dae S. Kim, Kyong H. Park, Seung-Kuk Baek, Soon Y. Kwon, Sang W. Shin, Kwang Y. Jung, Chul Y. Kim, Yeol H. Kim, Nam J. Lee, Jun S. Kim, In S. Kim
      Onkologie.2012; 35(11): 673.     CrossRef
    • Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy
      Seok-Hyun Kim, Gyeong-Won Lee, Min Jeong Lee, Yu Ji Cho, Yi Yeong Jeong, Ho-Cheol Kim, Jong Duk Lee, Young Sil Hwang, In-Suk Kim, Suee Lee, Sung Yong Oh
      Lung Cancer.2012; 77(3): 578.     CrossRef
    • Common genetic polymorphisms of microRNA biogenesis pathway genes and breast cancer survival
      Hyuna Sung, Sujee Jeon, Kyoung-Mu Lee, Sohee Han, Minkyo Song, Ji-Yeob Choi, Sue K Park, Keun-Young Yoo, Dong-Young Noh, Sei-Hyun Ahn, Daehee Kang
      BMC Cancer.2012;[Epub]     CrossRef
    • Socioeconomic inequalities in completion of hepatitis B vaccine series among Korean women: Results from a nationwide interview survey
      Boyoung Park, Kui Son Choi, Hoo-Yeon Lee, Jae Kwan Jun, Eun-Cheol Park
      Vaccine.2012; 30(40): 5844.     CrossRef
    • Comparison between screen-detected and symptomatic breast cancers according to molecular subtypes
      Jiyoung Kim, SeKyung Lee, SooYoun Bae, Min-Young Choi, Jeonghui Lee, Seung Pil Jung, Sangmin Kim, Jun-Ho Choe, Jung-Han Kim, Jee Soo Kim, Jeong Eon Lee, Seok Jin Nam, Jung-Hyun Yang
      Breast Cancer Research and Treatment.2012; 131(2): 527.     CrossRef
    • Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2009
      Kyu-Won Jung, Sohee Park, Hyun-Joo Kong, Young-Joo Won, Joo Young Lee, Hong Gwan Seo, Jin-Soo Lee
      Cancer Research and Treatment.2012; 44(1): 11.     CrossRef
    • Korean Guidelines for Colorectal Cancer Screening and Polyp Detection
      Bo In Lee, Sung Pil Hong, Seong-Eun Kim, Se Hyung Kim, Hyun-Soo Kim, Sung Noh Hong, Dong-Hoon Yang, Sung Jae Shin, Suck-Ho Lee, Young-Ho Kim, Dong Il Park, Hyun Jung Kim, Suk-Kyun Yang, Hyo Jong Kim, Hae Jeong Jeon
      The Korean Journal of Gastroenterology.2012; 59(2): 65.     CrossRef
    • Statistics of hematologic malignancies in Korea: incidence, prevalence and survival rates from 1999 to 2008
      Hyeon Jin Park, Eun-Hye Park, Kyu-Won Jung, Hyun-Joo Kong, Young-Joo Won, Joo Young Lee, Jong Hyung Yoon, Byung-Kiu Park, Hyewon Lee, Hyeon-Seok Eom, Sohee Park
      The Korean Journal of Hematology.2012; 47(1): 28.     CrossRef
    • Relationship between Positron Emission Tomography Uptake and Macroscopic Findings of Colorectal Cancer
      So Young Kim, Sun-Young Lee, Hwa-Kyung Lim, Ji Young Lee, Sung Noh Hong, Jeong Hwan Kim, In Kyung Sung, Hyung Seok Park, Chan Sup Shim, Choon Jo Jin, Hyun Woo Chung, Young So
      Intestinal Research.2012; 10(2): 168.     CrossRef
    • Oncologic Outcome After Preoperative Chemoradiotherapy in Patients With Pathologic T0 (ypT0) Rectal Cancer
      Tae Young Jang, Chang Sik Yu, Yong Sik Yoon, Seok-Byung Lim, Seung-Mo Hong, Tae Won Kim, Jong Hoon Kim, Jin Cheon Kim
      Diseases of the Colon & Rectum.2012; 55(10): 1024.     CrossRef
    • Prognostic Relevance of the Expression of CA IX, GLUT-1, and VEGF in Ovarian Epithelial Cancers
      Kyungbin Kim, Won Young Park, Jee Yeon Kim, Mee Young Sol, Dong Hun Shin, Do Youn Park, Chang Hun Lee, Jeong Hee Lee, Kyung Un Choi
      Korean Journal of Pathology.2012; 46(6): 532.     CrossRef
    • Safety and Efficacy of Fast‐track Surgery in Laparoscopic Distal Gastrectomy for Gastric Cancer: A Randomized Clinical Trial
      Jong Won Kim, Whan Sik Kim, Jae‐Ho Cheong, Woo Jin Hyung, Seung‐Ho Choi, Sung Hoon Noh
      World Journal of Surgery.2012; 36(12): 2879.     CrossRef
    • Current status of the National Cancer Screening Program for cervical cancer in Korea, 2009
      Young Hwa Lee, Kui Son Choi, Hoo-Yeon Lee, Jae Kwan Jun
      Journal of Gynecologic Oncology.2012; 23(1): 16.     CrossRef
    • Korean Guidelines for Colorectal Cancer Screening and Polyp Detection
      Bo-In Lee, Sung Pil Hong, Seong-Eun Kim, Se Hyung Kim, Hyun-Soo Kim, Sung Noh Hong, Dong-Hoon Yang, Sung Jae Shin, Suck-Ho Lee, Dong Il Park, Young-Ho Kim, Hyun Jung Kim, Suk-Kyun Yang, Hyo Jong Kim, Hae Jeong Jeon
      Clinical Endoscopy.2012; 45(1): 25.     CrossRef
    • De Novo Malignancies After Liver Transplantation: Incidence Comparison With the Korean Cancer Registry
      H.W. Park, S. Hwang, C.S. Ahn, K.H. Kim, D.B. Moon, T.Y. Ha, G.W. Song, D.H. Jung, G.C. Park, J.M. Namgoong, S.Y. Yoon, C.S. Park, Y.H. Park, H.J. Lee, S.G. Lee
      Transplantation Proceedings.2012; 44(3): 802.     CrossRef
    • Adjuvant Chemotherapy With or Without Pelvic Radiotherapy After Simultaneous Surgical Resection of Rectal Cancer With Liver Metastases: Analysis of Prognosis and Patterns of Recurrence
      Ho Jung An, Chang Sik Yu, Sung-Cheol Yun, Byung Woog Kang, Yong Sang Hong, Jae-Lyun Lee, Min-Hee Ryu, Heung Moon Chang, Jin Hong Park, Jong Hoon Kim, Yoon-Koo Kang, Jin Cheon Kim, Tae Won Kim
      International Journal of Radiation Oncology*Biology*Physics.2012; 84(1): 73.     CrossRef
    • Differences in Postoperative Pathological Outcomes between Prostate Cancers Diagnosed at Initial and Repeat Biopsy
      In Ho Khang, Yun Beom Kim, Seung Ok Yang, Jeong Ki Lee, Tae Young Jung
      Korean Journal of Urology.2012; 53(8): 531.     CrossRef
    • Review of Molecular Markers for Thyroid Cancer
      Jae-Joon Han, Ki-Sook Hong
      The Ewha Medical Journal.2012; 35(1): 3.     CrossRef
    • Changes in Prostate Cancer Aggressiveness over a 12-Year Period in Korea
      Doejung Kim, Daeheon Choi, Ju Hyun Lim, Jong Hyun Yoon, In Gab Jeong, Dalsan You, Jun Hyuk Hong, Hanjong Ahn, Choung-Soo Kim
      Korean Journal of Urology.2012; 53(10): 680.     CrossRef
    • Comparison of outcomes between radical hysterectomy followed by tailored adjuvant therapy versus primary chemoradiation therapy in IB2 and IIA2 cervical cancer
      Jeong-Yeol Park, Dae-Yeon Kim, Jong-Hyeok Kim, Yong-Man Kim, Young-Tak Kim, Young-Seok Kim, Ha Jeong Kim, Jeong-Won Lee, Byoung-Gie Kim, Duk-Soo Bae, Seung Jae Huh, Joo-Hyun Nam
      Journal of Gynecologic Oncology.2012; 23(4): 226.     CrossRef
    • Laparoscopic Compared With Open Radical Hysterectomy in Obese Women With Early-Stage Cervical Cancer
      Jeong-Yeol Park, Dae-Yeon Kim, Jong-Hyeok Kim, Yong-Man Kim, Young-Tak Kim, Joo-Hyun Nam
      Obstetrics & Gynecology.2012; 119(6): 1201.     CrossRef
    • Current Management and Future Strategies of Gastric Cancer
      Joong Ho Lee, Kyung Min Kim, Jae-Ho Cheong, Sung Hoon Noh
      Yonsei Medical Journal.2012; 53(2): 248.     CrossRef
    • Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer
      Mi-Jung Kim, Hye Seung Lee, Jee Hyun Kim, Yu Jung Kim, Ji Hyun Kwon, Jeong-Ok Lee, Soo-Mee Bang, Kyoung Un Park, Duck-Woo Kim, Sung-Bum Kang, Jae-Sung Kim, Jong Seok Lee, Keun-Wook Lee
      BMC Cancer.2012;[Epub]     CrossRef
    • Chemopreventive Effects ofRubus coreanusMiquel on Prostate Cancer
      Yuri KIM, Jina KIM, Seung-Min LEE, Hyun Ah LEE, Seolhyun PARK, Yesl KIM, Jung-Hyun KIM
      Bioscience, Biotechnology, and Biochemistry.2012; 76(4): 737.     CrossRef
    • Correlation Between Body Mass Index and Prevalence of Hereditary Nonpolyposis Colorectal Cancer in Korean Patients With Endometrial Cancer
      Heon Jong Yoo, Jungnam Joo, Sang-Soo Seo, Sokbom Kang, Chong Woo Yoo, Sang-Yoon Park, Myong Cheol Lim
      International Journal of Gynecological Cancer.2012; 22(2): 267.     CrossRef
    • Safety and feasibility of adjuvant chemotherapy with S-1 for Korean patients with curatively resected advanced gastric cancer
      Jae Ho Jeong, Min-Hee Ryu, Baek-Yeol Ryoo, Sung Sook Lee, Inkeun Park, Sang Hong Lee, Kab Choong Kim, Jeong Hwan Yook, Sung Tae Oh, Byung Sik Kim, Yoon-Koo Kang
      Cancer Chemotherapy and Pharmacology.2012; 70(4): 523.     CrossRef
    • Population-based survival data for brain tumors in Korea
      Kyu-Won Jung, Heon Yoo, Hyun-Joo Kong, Young-Joo Won, Sohee Park, Seung Hoon Lee
      Journal of Neuro-Oncology.2012; 109(2): 301.     CrossRef
    • Surgical stress after robot-assisted distal gastrectomy and its economic implications
      J Y Park, M J Jo, B-H Nam, Y Kim, B W Eom, H M Yoon, K W Ryu, Y-W Kim, J H Lee
      British Journal of Surgery.2012; 99(11): 1554.     CrossRef
    • Awareness and Practice of Breast Self-examination among Korean Women: Results from a Nationwide Survey
      Bit-Na Yoo, Kui-Son Choi, Kyu-Won Jung, Jae-Kwan Jun
      Asian Pacific Journal of Cancer Prevention.2012; 13(1): 123.     CrossRef
    • Invasive Pleomorphic Lobular Carcinoma of the Breast: Clinicopathologic Characteristics and Prognosis Compared with Invasive Ductal Carcinoma
      Seung Pil Jung, Se Kyoung Lee, Sangmin Kim, Min-Young Choi, Soo Youn Bae, Jiyoung Kim, Minkuk Kim, Won Ho Kil, Eun Yoon Cho, Jun-Ho Choe, Jung-Han Kim, Jee Soo Kim, Seok Jin Nam, Jeong Eon Lee
      Journal of Breast Cancer.2012; 15(3): 313.     CrossRef
    • Clinical Experience with Limited Lymph Node Dissection for Prostate Cancer in Korea: Single Center Comparison of 247 Open and 354 Robot-Assisted Laparoscopic Radical Prostatectomy Series
      Daeheon Choi, Doejung Kim, Yoon Soo Kyung, Ju Hyun Lim, Sang Hoon Song, Dalsan You, In Gab Jeong, Choung-Soo Kim
      Korean Journal of Urology.2012; 53(11): 755.     CrossRef
    • Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum
      J H Yi, J Lee, J Lee, S H Park, J O Park, D-S Yim, Y S Park, H Y Lim, W K Kang
      British Journal of Cancer.2012; 106(9): 1469.     CrossRef
    • Impact of Clinicopathologic Factors on Subclinical Central Lymph Node Metastasis in Papillary Thyroid Microcarcinoma
      Bo-Yeon Kim, Chan-Hee Jung, Jae-Wook Kim, Seung-Won Lee, Chul-Hee Kim, Sung-Koo Kang, Ji-Oh Mok
      Yonsei Medical Journal.2012; 53(5): 924.     CrossRef
    • Amplification of theUQCRFS1Gene in Gastric Cancers
      Kyong Hwa Jun, Su Young Kim, Jung Hwan Yoon, Jae Hwi Song, Won Sang Park
      Journal of Gastric Cancer.2012; 12(2): 73.     CrossRef
    • Proposal for Creating a Guideline for Cancer Registration of Microinvasive Tumors of the Breast and Ovary (II)
      Jin Hee Sohn, Gyungyub Gong, Kyu Rae Kim, Chang Suk Kang, Youn Soo Lee, Jin Man Kim, Woo Hee Jung, Kwang Sun Suh
      Korean Journal of Pathology.2012; 46(3): 226.     CrossRef
    • Current Status of Targeted Therapy for Advanced Renal Cell Carcinoma
      In-Chang Cho, Jinsoo Chung
      Korean Journal of Urology.2012; 53(4): 217.     CrossRef
    • The premier statistical report of hematologic malignancies in Korea
      Hee-Je Kim
      The Korean Journal of Hematology.2012; 47(1): 1.     CrossRef
    • Clinical significance of preoperative neutrophil-lymphocyte versus platelet-lymphocyte ratio in patients with operable colorectal cancer
      Hyuk-Chan Kwon, Sung Hyun Kim, Sung Yong Oh, Suee Lee, Ji Hyun Lee, Hong-Jo Choi, Ki-Jae Park, Mee Sook Roh, Seung-Geun Kim, Hyo-Jin Kim, Jong Hoon Lee
      Biomarkers.2012; 17(3): 216.     CrossRef
    • Prognostic Significance of Serum Levels of Vascular Endothelial Growth Factor and Insulin-Like Growth Factor-1 in Advanced Gastric Cancer Patients Treated with FOLFOX Chemotherapy
      Sung Yong Oh, Hyuk-Chan Kwon, Sung Hyun Kim, Suee Lee, Ji Hyun Lee, Christian A. Graves, Kevin Camphausen, Hyo-Jin Kim
      Chemotherapy.2012; 58(6): 426.     CrossRef
    • Prostate Stem Cell Antigen Single Nucleotide Polymorphisms Influence Risk of Estrogen Receptor Negative Breast Cancer in Korean Females
      Sook-Young Kim, Jae-Young Yoo, Ae-Sun Shin, Yeon-Ju Kim, Eun-Sook Lee, Yeon-Su Lee
      Asian Pacific Journal of Cancer Prevention.2012; 13(1): 41.     CrossRef
    • Adjuvant Chemotherapy and Survival of Elderly Korean Patients with Breast Carcinoma
      Seung Pil Jung, Jeong Eon Lee, Se Kyung Lee, Sangmin Kim, Min-Young Choi, Soo Youn Bae, Jiyoung Kim, Won Ho Kil, Jun-Ho Choe, Jung-Han Kim, Jee Soo Kim, Seok Jin Nam
      Journal of Breast Cancer.2012; 15(3): 296.     CrossRef
    • Multiplicative synergistic risk of hepatocellular carcinoma development among hepatitis B and C co-infected subjects in HBV endemic area: a community-based cohort study
      Jin-Kyoung Oh, Hai-Rim Shin, Min Kyung Lim, Heeyoun Cho, Dong-Il Kim, Youngmee Jee, Haesun Yun, Keun-Young Yoo
      BMC Cancer.2012;[Epub]     CrossRef
    • Laparoscopic versus open radical hysterectomy for elderly patients with early-stage cervical cancer
      Jeong-Yeol Park, Dae-Yeon Kim, Jong-Hyeok Kim, Yong-Man Kim, Young-Tak Kim, Joo-Hyun Nam
      American Journal of Obstetrics and Gynecology.2012; 207(3): 195.e1.     CrossRef
    • Treatment outcome in patients with vulvar cancer: comparison of concurrent radiotherapy to postoperative radiotherapy
      Jayoung Lee, Sung Hwan Kim, Giwon Kim, Mina Yu, Dong-Choon Park, Joo-Hee Yoon, Sei-Chul Yoon
      Radiation Oncology Journal.2012; 30(1): 20.     CrossRef
    • Discovery and Evaluation of Polymorphisms in theAKT2andAKT3Promoter Regions for Risk of Korean Lung Cancer
      Jae Sook Sung, Kyong Hwa Park, Seung Tae Kim, Yeul Hong Kim
      Genomics & Informatics.2012; 10(3): 167.     CrossRef
    • Value of Surveillance 18F-FDG PET/CT in Colorectal Cancer: Comparison with Conventional Imaging Studies
      Eun Kyoung Choi, Ie Ryung Yoo, Hye Lim Park, Hyun Su Choi, Eun Ji Han, Sung Hoon Kim, Soo Kyo Chung, Joo Hyun O
      Nuclear Medicine and Molecular Imaging.2012; 46(3): 189.     CrossRef
    • Proteins involved in DNA damage response pathways and survival of stage I non-small-cell lung cancer patients
      C.M. Choi, S.C. Yang, H.J. Jo, S.Y. Song, Y.J. Jeon, T.W. Jang, D.J. Kim, S.H. Jang, S.H. Yang, Y.D. Kim, K.H. Lee, S.J. Jang, Y.T. Kim, D.K. Kim, D.H. Chung, L. Kim, H.S. Nam, J.H. Cho, H.J. Kim, J.S. Ryu
      Annals of Oncology.2012; 23(8): 2088.     CrossRef
    • Prognostic Signifi cance of the Lymph Node Ratio Regarding Recurrence and Survival in Rectal Cancer Patients Treated with Postoperative Chemoradiotherapy
      Ji-Yoon Kim, Su-Mi Chung, Byung-Ock Choi, In-Kyu Lee, Chang-Hyeok An, Jong-Man Won, Mi-Ryeong Ryu
      Gut and Liver.2012; 6(2): 203.     CrossRef
    • Surgical outcomes and prognostic factors influencing long-term survival in patients with gallbladder cancer
      Sung Ha Lee, Jae Do Yang, Hong Pil Hwang, Hee Chul Yu, Baik Hwan Cho
      Korean Journal of Hepato-Biliary-Pancreatic Surgery.2012; 16(2): 59.     CrossRef
    • Korean Guidelines for Colorectal Cancer Screening and Polyp Detection
      Bo In Lee, Sung Pil Hong, Seong Eun Kim, Se Hyung Kim, Hyun Soo Kim, Sung Noh Hong, Dong Hoon Yang, Sung Jae Shin, Suck Ho Lee, Young Ho Kim, Dong Il Park, Hyun Jung Kim, Suk Kyun Yang, Hyo Jong Kim, Hae Jeong Jeon
      Journal of the Korean Society of Radiology.2012; 66(4): 385.     CrossRef
    • Promoter methylation of RASSF1A modulates the effect of the microtubule-targeting agent docetaxel in breast cancer
      EUN YOUNG GIL, UK HYUN JO, HOISEON JEONG, YOUNG MI WHANG, OK HEE WOO, KYU RAN CHO, JAE HONG SEO, AEREE KIM, EUN SOOK LEE, INSONG KOH, YEUL HONG KIM, KYONG HWA PARK
      International Journal of Oncology.2012; 41(2): 611.     CrossRef
    • Oxaliplatin, 5-fluorouracil and leucovorin (modified FOLFOX-6) as first-line chemotherapy for advanced gastric cancer patients with poor performance status
      HYEONG SU KIM, JUNG HAN KIM, HEE JUN KIM, HYUN JOO JANG, JIN BAE KIM, JI WON KIM, SO YOUNG JUNG, BYUNG CHUN KIM, DAE HYUN YANG, SOAH PARK, KEONG JU KIM, SOON IL LEE, DAE YOUNG ZANG
      Oncology Letters.2012; 3(2): 425.     CrossRef
    • Irinotecan, leucovorin and 5-fluorouracil (modified FOLFIRI) as salvage chemotherapy for frail or elderly patients with advanced gastric cancer
      JUNG HAN KIM, HYEONG SU KIM, A RUM HAN, IN HO MOH, DOO CHEOL CHUNG, DAE RO CHOI, HYUN JOO JANG, JIN BAE KIM, DAE HYUN YANG, SOON IL LEE, DAE YOUNG ZANG
      Oncology Letters.2012; 4(4): 751.     CrossRef
    • Policy on Hospice and Palliative Care in Korea
      Yoon-Jung Chang
      The Korean Journal of Hospice and Palliative Care.2012; 15(4): 183.     CrossRef
    • Prognostic Factors of Second and Third Line Chemotherapy Using 5-FU with Platinum, Irinotecan, and Taxane for Advanced Gastric Cancer
      Ji Soo Park, Jae Yun Lim, Seung Kyo Park, Min Kyung Kim, Hee Sung Ko, Sun Och Yoon, Jong Won Kim, Seung Ho Choi, Jae Yong Cho
      Cancer Research and Treatment.2011; 43(4): 236.     CrossRef
    • Nutritional Consequences and Management After Gastrectomy
      Jae-Moon Bae
      Hanyang Medical Reviews.2011; 31(4): 254.     CrossRef
    • Gastric Cancer Epidemiology in Korea
      Aesun Shin, Jeongseon Kim, Sohee Park
      Journal of Gastric Cancer.2011; 11(3): 135.     CrossRef
    • Trends in Cancer Screening Rates among Korean Men and Women: Results from the Korean National Cancer Screening Survey (KNCSS), 2004-2010
      Eun-Ha Lee, Hoo-Yeon Lee, Kui Son Choi, Jae Kwan Jun, Eun-Cheol Park, Jin Soo Lee
      Cancer Research and Treatment.2011; 43(3): 141.     CrossRef
    • Aging over 70 Years Is Not a Decisively Dismal Prognostic Factor in Gastric Cancer Surgery
      Sung-Il Cho, You-Jin Jang, Jong-Han Kim, Sung-Soo Park, Seong-Heum Park, Seung-Joo Kim, Chong-Suk Kim, Young-Jae Mok
      Journal of Gastric Cancer.2011; 11(4): 200.     CrossRef
    • Adjuvant Chemotherapy Using the FOLFOX Regimen in Colon Cancer
      Hyeong-Joon Jeon, Jin-Hee Woo, Hak-Yoon Lee, Ki-Jae Park, Hong-Jo Choi
      Journal of the Korean Society of Coloproctology.2011; 27(3): 140.     CrossRef
    • Gemcitabine Plus Platinum Combination Chemotherapy for Elderly Patients with Advanced Non-small Cell Lung Cancer: A Retrospective Analysis
      Sang Hoon Chun, Ji Eun Lee, Mi Hee Park, Jin-Hyoung Kang, Young Kyoon Kim, Young-Pil Wang, Jae Kil Park, Hoon-Kyo Kim
      Cancer Research and Treatment.2011; 43(4): 217.     CrossRef
    • Retrospective analysis of treatment outcomes after postoperative chemoradiotherapy in advanced gastric cancer
      Sup Kim, Jun-Sang Kim, Hyun-Yong Jeong, Seung-Moo Noh, Ki-Whan Kim, Moon-June Cho
      Radiation Oncology Journal.2011; 29(4): 252.     CrossRef
    • Role of Adjuvant Chemoradiotherapy for Resected Extrahepatic Biliary Tract Cancer
      Tae Hyun Kim, Sung-Sik Han, Sang-Jae Park, Woo Jin Lee, Sang Myung Woo, Sung Ho Moon, Tae Yoo, Sang Soo Kim, Seong Hoon Kim, Eun Kyung Hong, Dae Yong Kim, Joong-Won Park
      International Journal of Radiation Oncology*Biology*Physics.2011; 81(5): e853.     CrossRef
    • Effectiveness of Adjuvant Chemotherapy with 5-FU/Leucovorin and Prognosis in Stage II Colon Cancer
      Sun Hee Jee, Sun Mi Moon, Ui Sup Shin, Hoe Min Yang, Dae-Yong Hwang
      Journal of the Korean Society of Coloproctology.2011; 27(6): 322.     CrossRef
    • Risk Factors and Control Strategies for the Rapidly Rising Rate of Breast Cancer in Korea
      Sue K. Park, Yeonju Kim, Daehee Kang, En-Joo Jung, Keun-Young Yoo
      Journal of Breast Cancer.2011; 14(2): 79.     CrossRef
    • Alternative Medical Treatment for Radioiodine-Refractory Thyroid Cancers
      Jin Chul Paeng, Keon Wook Kang, Do Joon Park, So Won Oh, June-Key Chung
      Nuclear Medicine and Molecular Imaging.2011; 45(4): 241.     CrossRef
    • A Phase II Study of Modified FOLFOX4 for Colorectal Cancer Patients with Peritoneal Carcinomatosis
      Dong Hyun Lee, Sung Yong Oh, Yu Rim Lee, Seok Jae Huh, Hyun Hwa Yoon, Sung Hyun Kim, Suee Lee, Ji Hyun Lee, Young Kim, Hyo-Jin Kim, Hyuk-Chan Kwon
      Cancer Research and Treatment.2011; 43(4): 225.     CrossRef
    • Pulmonary Metastasis from Rectal Cancer on Chest CT Is Correlated with 3T MRI Primary Tumor Location
      Na Yeon Han, Min Ju Kim, Beon Jin Park, Deuk Jae Sung, Kyoo Byung Chung, Yu-Whan Oh
      Journal of the Korean Society of Radiology.2011; 65(2): 151.     CrossRef

    • PubReader PubReader
    • ePub LinkePub Link
    • Cite
      CITE
      export Copy Download
      Close
      Download Citation
      Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

      Format:
      • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
      • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
      Include:
      • Citation for the content below
      Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2008
      Cancer Res Treat. 2011;43(1):1-11.   Published online March 31, 2011
      Close
    • XML DownloadXML Download
    Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2008
    Image Image Image Image Image
    Fig. 1 Annual age-standardized cancer incidence and death rates for all sites by sex during 1983-2008 in Korea. Age-standardization was based on the World Health Organization (WHO) world standard population.
    Fig. 2 Trend of age-standardized cancer incidence for selected cancers by sex during 1999-2008 in Korea. Age-standardization was based on the World Health Organization (WHO) world standard population. (A) Male. (B) Female.
    Fig. 3 Age-specific incidence rates of major cancers during 2008 in Korea. (A) Male. (B) Female.
    Fig. 4 Annual age-standardized cancer mortality for selected cancers by sex during 1983-2008 in Korea. Age-standardization was based on the World Health Organization (WHO) world standard population. (A) Male. (B) Female.
    Fig. 5 Number of prevalent cases by time since diagnosis for major cancer sites on January 1, 2009 in Korea.
    Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2008
    Sites New cases Deaths 10-yr prevalent cases a)



    Both sexes Male Female Both sexes Male Female Both sexes Male Female
    All sites 178,816 93,017 85,799 68,912 43,785 25,127 724,663 334,329 390,334
    Lip, oral cavity, and pharynx 2,557 1,899 658 969 761 208 11,304 7,728 3,576
    Esophagus 2,181 1,986 195 1,385 1,244 141 5,216 4,717 499
    Stomach 28,078 18,898 9,180 10,312 6,712 3,600 134,722 89,616 45,106
    Colon and rectum 22,623 13,536 9,087 6,802 3,809 2,993 103,033 60,448 42,585
    Liver 15,663 11,776 3,887 11,292 8,512 2,780 36,036 27,085 8,951
    Gallbladder b) 4,378 2,149 2,229 3,459 1,698 1,761 9,935 5,076 4,859
    Pancreas 4,320 2,404 1,916 3,767 2,135 1,632 4,780 2,663 2,117
    Larynx 1,073 998 75 409 364 45 6,385 5,977 408
    Lung 18,774 13,384 5,390 14,791 10,899 3,892 34,926 23,465 11,461
    Breast 12,659 75 12,584 1,731 13 1,718 79,468 381 79,087
    Cervix uteri 3,888 - 3,888 954 - 954 33,102 - 33,102
    Corpus uteri 1,562 - 1,562 210 - 210 9,084 - 9,084
    Ovary 1,816 - 1,816 834 - 834 9,732 - 9,732
    Prostate 6,471 6,471 - 1,168 1,168 - 23,940 23,940 -
    Testis 176 176 - 14 14 - 1,408 1,408 -
    Kidney 3,228 2,220 1,008 655 461 194 15,243 10,265 4,978
    Bladde 3,230 2,582 648 1,007 752 255 18,260 14,845 3,415
    Brain and CNS 1,620 876 744 1,040 568 472 6,273 3,289 2,984
    Thyroid 26,923 4,275 22,648 347 108 239 107,693 15,252 92,441
    Hodgkin lymphoma 210 127 83 46 31 15 1,253 796 457
    Non-Hodgkin lymphoma 3,475 1,936 1,539 1,343 814 529 16,142 8,873 7,269
    Multiple myeloma 893 480 413 615 316 299 2,464 1,295 1,169
    Leukemia 2,561 1,432 1,129 1,507 867 640 9,936 5,442 4,494
    Other and ill-defined 10,457 5,337 5,120 4,255 2,539 1,716 44,328 21,768 22,560
    Sites Crude incidence rates/100,000 Age-standardized incidence rates/100,000 a)


    Both sexes Male Female Both sexes Male Female
    All sites 361.9 375.7 348.1 271.1 318.5 245.3
    Lip, oral cavity, and pharynx 5.2 7.7 2.7 3.9 6.4 1.9
    Esophagus 4.4 8.0 0.8 3.3 6.9 0.5
    Stomach 56.8 76.3 37.2 42.2 63.8 24.9
    Colon and rectum 45.8 54.7 36.9 34.1 45.9 24.7
    Liver 31.7 47.6 15.8 23.7 38.9 10.5
    Gallbladder b) 8.9 8.7 9.0 6.4 7.5 5.5
    Pancreas 8.7 9.7 7.8 6.3 8.3 4.8
    Larynx 2.2 4.0 0.3 1.6 3.4 0.2
    Lung 38.0 54.1 21.9 27.7 46.9 13.9
    Breast 25.6 0.3 51.1 18.7 0.3 36.8
    Cervix uteri 7.9 - 15.8 5.8 - 11.2
    Corpus uteri 3.2 - 6.3 2.4 - 4.6
    Ovary 3.7 - 7.4 2.8 - 5.5
    Prostate 13.1 26.1 - 9.6 23.0 -
    Testis 0.4 0.7 - 0.4 0.7 -
    Kidney 6.5 9.0 4.1 5.0 7.4 3.0
    Bladder 6.5 10.4 2.6 4.7 9.0 1.6
    Brain and CNS 3.3 3.5 3.0 2.9 3.3 2.6
    Thyroid 54.5 17.3 91.9 40.8 13.1 68.6
    Hodgkin lymphoma 0.4 0.5 0.3 0.4 0.5 0.3
    Non-Hodgkin lymphoma 7.0 7.8 6.2 5.5 6.7 4.6
    Multiple myeloma 1.8 1.9 1.7 1.4 1.6 1.2
    Leukemia 5.2 5.8 4.6 5.0 5.7 4.3
    Other and ill-defined 21.2 21.6 20.8 16.5 19.1 4.3
    Rank Cause of deaths No. of death Percent of all deaths Age-standardized death rate a)
    All causes 246,113 100 365.3
    1 Cancer 68,912 28 101.0
    2 Cerebrovascular disease 27,932 11.3 39.1
    3 Heart disease 21,429 8.7 30.6
    4 Intentional self harm (suicide) 12,858 5.2 20.3
    5 Diabetes mellitus 10,234 4.2 14.5
    6 Chronic lower respiratory diseases 7,338 3.0 10.1
    7 Transport accidents 7,287 3.0 12.1
    8 Disease of liver 7,164 2.9 10.7
    9 Pneumonia 5,461 2.2 7.7
    10 Hypertensive diseases 4,724 1.9 6.6
    Others 72,774 29.6 112.6
    Sites Crude mortality rates/100,000 Age-standardized mortality rates/100,000 a)


    Both sexes Male Female Both sexes Male Female
    All sites 139.5 176.9 101.9 101.0 154.1 63.5
    Lip, oral cavity, and pharynx 2.0 3.1 0.8 1.4 2.6 0.5
    Esophagus 2.8 5.0 0.6 2.1 4.4 0.3
    Stomach 20.9 27.1 14.6 14.8 23.5 8.7
    Colon and rectum 13.8 15.4 12.1 9.8 13.5 7.3
    Liver 22.9 34.4 11.3 16.9 28.5 7.2
    Gallbladder b) 7.0 6.9 7.1 4.9 6.1 4.1
    Pancreas 7.6 8.6 6.6 5.5 7.5 4.0
    Larynx 0.8 1.5 0.2 0.6 1.3 0.1
    Lung 29.9 44.0 15.8 21.3 38.7 9.4
    Breast 3.5 0.1 7.0 2.6 0.0 4.9
    Cervix uteri 1.9 - 3.9 1.4 - 2.5
    Corpus uteri 0.4 - 0.9 0.3 - 0.6
    Ovary 1.7 - 3.4 1.2 - 2.3
    Prostate 2.4 4.7 - 1.6 4.6 -
    Testis 0.0 0.1 - 0.0 0.1 -
    Kidney 1.3 1.9 0.8 1.0 1.6 0.5
    Bladder 2.0 3.0 1.0 1.4 2.8 0.5
    Brain and CNS 2.1 2.3 1.9 1.7 2.0 1.4
    Thyroid 0.7 0.4 1.0 0.5 0.4 0.5
    Hodgkin lymphoma 0.1 0.1 0.1 0.1 0.1 0.0
    Non-Hodgkin lymphoma 2.7 3.3 2.1 2.0 2.8 1.4
    Multiple myeloma 1.2 1.3 1.2 0.9 1.1 0.8
    Leukemia 3.1 3.5 2.6 2.6 3.2 2.0
    Other and ill-defined 8.6 10.3 7.0 6.3 9.1 4.4
    Sites Year APC a)

    1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
    All sites 210.5 205.1 216.7 220.1 227.1 234.1 246.7 250.5 260.8 271.1 3.1 b)
    Lip, oral cavity, and pharynx 3.6 4.4 3.6 3.7 3.8 3.8 3.8 3.7 3.8 3.9 0.1
    Esophagus 4.1 3.7 3.9 3.8 3.6 3.5 3.5 3.4 3.3 3.3 -2.1 b)
    Stomach 43.6 42.3 44.0 43.6 43.2 41.1 44.3 42.7 41.6 42.2 -0.3
    Colon and rectum 20.4 21.0 22.9 24.7 26.8 28.5 30.8 32.2 33.3 34.1 6.4 b)
    Liver 27.9 26.7 27.3 26.5 25.7 25.5 25.8 24.5 24.2 23.7 -1.7 b)
    Gallbladder c) 6.5 6.4 6.7 6.7 6.7 6.9 7.1 6.6 6.5 6.4 0.1
    Pancreas 5.6 5.5 5.5 5.8 5.8 6.0 6.3 6.1 6.3 6.3 1.7
    Larynx 2.3 2.2 2.4 2.2 2.1 1.9 2.0 1.8 1.8 1.6 -3.9 b)
    Lung 28.5 27.7 28.3 28.5 27.8 28.7 28.9 28.6 28.2 27.7 0.0
    Breast 10.7 10.8 12.7 13.9 14.2 14.9 16.1 16.8 17.9 18.7 6.5 b)
    Cervix uteri 8.5 7.9 8.3 7.7 7.4 6.8 6.5 6.3 5.7 5.8 -4.6 b)
    Corpus uteri 1.4 1.3 1.5 1.7 1.9 1.9 2.0 2.1 2.1 2.4 6.0 b)
    Ovary 2.7 2.5 2.5 2.6 2.7 2.7 2.8 2.8 3.0 2.8 1.6 b)
    Prostate 3.1 2.7 3.6 3.9 4.8 5.9 6.3 7.2 8.5 9.6 15.2 b)
    Testis 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.4 0.4 0.4 3.5 b)
    Kidney 3.0 2.9 3.3 3.4 3.5 3.7 4.1 4.4 4.7 5.0 6.4 b)
    Bladder 4.6 4.6 4.9 4.7 5.1 5.1 5.1 4.9 4.9 4.7 0.5
    Brain and CNS 2.9 2.8 2.8 2.6 2.9 2.9 3.1 2.9 3.1 2.9 1.0 b)
    Thyroid 6.3 6.1 7.9 9.5 12.7 17.2 20.6 25.3 32.6 40.8 25.1 b)
    Hodgkin lymphoma 0.2 0.3 0.3 0.3 0.3 0.4 0.3 0.3 0.4 0.4 4.5 b)
    Non-Hodgkin lymphoma 4.5 4.2 4.5 4.6 4.9 5.2 5.3 5.5 5.5 5.5 3.3 b)
    Multiple myeloma 1.0 1.0 1.1 1.1 1.1 1.2 1.3 1.3 1.4 1.4 4.0 b)
    Leukemia 4.7 4.3 4.7 4.8 4.7 4.8 4.7 4.9 4.8 5.0 0.9 b)
    Other and ill-defined 14.3 13.5 13.9 13.5 15.1 15.1 16.0 15.9 16.8 16.5 -
    Sites Year APC a)

    1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
    All sites 285.0 276.7 288.3 290.0 294.2 298.6 310.4 308.6 314.3 318.5 1.5 b)
    Lip, oral cavity, and pharynx 6.1 7.1 6.0 6.2 6.5 6.1 6.0 6.1 6.2 6.4 -0.4
    Esophagus 8.8 8.0 8.3 8.2 7.7 7.7 7.6 7.2 6.9 6.9 -2.5 b)
    Stomach 66.2 65.0 67.2 66.6 65.9 62.2 66.7 65.2 62.8 63.8 -0.5
    Colon and rectum 26.2 27.2 29.6 32.9 35.2 37.8 40.9 43.0 44.8 45.9 7.0 b)
    Liver 46.8 44.7 45.1 43.9 42.3 42.1 42.6 40.1 39.5 38.9 -1.9 b)
    Gallbladder c) 8.1 7.8 8.2 8.1 7.8 8.4 8.7 8.1 7.9 7.5 -0.2
    Pancreas 7.8 7.6 7.6 7.9 7.7 8.0 8.3 8.0 8.2 8.3 0.9 b)
    Larynx 4.9 4.5 5.1 4.7 4.4 4.1 4.3 3.7 3.7 3.4 -3.8 b)
    Lung 51.4 49.8 51.1 51.0 49.9 50.8 50.8 49.1 48.5 46.9 -0.7 b)
    Breast 0.2 0.3 0.2 0.3 0.2 0.2 0.2 0.2 0.1 0.3 -2.2
    Prostate 8.4 7.2 9.5 10.1 12.3 15.0 15.7 17.8 20.7 23.0 13.7 b)
    Testis 0.6 0.5 0.6 0.6 0.6 0.6 0.6 0.7 0.7 0.7 3.4 b)
    Kidney 4.5 4.4 4.9 5.0 5.2 5.5 6.0 6.5 7.0 7.4 6.0 b)
    Bladder 9.0 9.0 9.4 9.0 9.7 9.8 9.7 9.5 9.3 9.0 0.3
    Brain and CNS 3.2 3.1 3.1 2.9 3.3 3.3 3.4 3.2 3.4 3.3 0.9
    Thyroid 2.1 1.9 2.4 2.7 3.7 4.8 5.9 7.5 9.9 13.1 24.5 b)
    Hodgkin lymphoma 0.4 0.4 0.4 0.3 0.4 0.5 0.4 0.4 0.5 0.5 2.8
    Non-Hodgkin lymphoma 5.8 5.5 5.8 5.8 6.2 6.6 6.4 6.8 6.9 6.7 2.5 b)
    Multiple myeloma 1.2 1.3 1.4 1.4 1.4 1.4 1.6 1.4 1.6 1.6 3.1 b)
    Leukemia 5.5 5.0 5.4 5.8 5.4 5.7 5.5 5.6 5.6 5.7 0.8
    Other and ill-defined 17.9 16.5 16.8 16.5 18.4 18.1 19.1 18.6 19.9 19.1 -
    Sites Year APC a)

    1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
    All sites 161.1 157.4 169.0 174.6 183.8 192.8 206.7 215.0 229.7 245.3 5.1 b)
    Lip, oral cavity, and pharynx 1.6 2.4 1.7 1.7 1.7 1.8 1.9 1.8 1.9 1.9 0.5
    Esophagus 0.6 0.6 0.6 0.5 0.6 0.5 0.4 0.5 0.5 0.5 -2.2 b)
    Stomach 26.7 25.2 26.2 26.3 25.9 24.7 26.8 25.0 24.7 24.9 -0.6
    Colon and rectum 16.4 16.4 17.9 18.8 20.4 21.4 22.8 23.9 24.2 24.7 5.3 b)
    Liver 12.3 11.8 12.2 11.8 11.5 11.3 11.3 11.1 11.0 10.5 -1.5 b)
    Gallbladder c) 5.3 5.5 5.7 5.8 5.8 5.9 6.0 5.5 5.6 5.5 0.2
    Pancreas 4.0 4.0 4.0 4.2 4.4 4.4 4.7 4.7 4.7 4.8 2.5 b)
    Larynx 0.4 0.3 0.3 0.3 0.3 0.3 0.3 0.2 0.2 0.2 -9.0 b)
    Lung 12.4 12.5 12.3 12.6 12.4 13.0 13.5 13.9 13.8 13.9 1.5 b)
    Breast 20.9 20.9 24.7 27.2 27.8 29.1 31.7 33.1 35.4 36.8 6.7 b)
    Cervix uteri 16.3 15.1 15.8 14.8 14.2 13.1 12.4 12.2 11.0 11.2 -4.5 b)
    Corpus uteri 2.8 2.6 3.0 3.3 3.8 3.7 3.9 4.0 4.2 4.6 6.2 b)
    Ovary 5.0 4.8 4.8 5.0 5.1 5.2 5.4 5.4 5.8 5.5 1.8 b)
    Kidney 1.7 1.8 1.9 2.0 2.1 2.2 2.5 2.7 2.8 3.0 6.5 b)
    Bladder 1.6 1.6 1.7 1.7 1.8 1.7 1.7 1.6 1.7 1.6 -0.1
    Brain and CNS 2.6 2.5 2.5 2.4 2.5 2.7 2.8 2.7 2.8 2.6 1.0
    Thyroid 10.4 10.1 13.2 16.2 21.7 29.5 35.2 43.0 55.2 68.6 25.4 b)
    Hodgkin lymphoma 0.1 0.2 0.2 0.2 0.2 0.2 0.2 0.3 0.3 0.3 7.1 b)
    Non-Hodgkin lymphoma 3.4 3.2 3.4 3.5 3.9 4.1 4.4 4.3 4.3 4.6 4.2 b)
    Multiple myeloma 0.8 0.8 0.9 0.8 1.0 1.0 1.2 1.1 1.2 1.2 5.3 b)
    Leukemia 3.9 3.8 4.1 4.0 4.1 4.1 4.0 4.3 4.1 4.3 1.1 b)
    Other and ill-defined 11.8 11.5 11.8 11.5 12.6 12.9 13.7 13.9 14.4 14.3 -
    Rank Age (yr)

    0-14 15-34 35-64 ≥65
    Males
    1 Leukemia (4.5) Thyroid (8.2) Stomach (92.1) Lung (447.5)
    2 Brain and CNS (2.3) Leukemia (3.3) Liver (69.5) Stomach (443.6)
    3 Non-Hodgkin lymphoma (1.4) Stomach (2.9) Colon and rectum (64.5) Colon and rectum (323.3)
    4 Kidney a) (0.5) Colon and rectum (2.7) Lung (41.4) Prostate (245.3)
    5 Testis a) (0.5) Non-Hodgkin lymphoma (2.4) Thyroid (30.0) Liver (211.6)
    Females
    1 Leukemia (3.7) Thyroid (44.5) Thyroid (166.0) Colon and rectum (161.9)
    2 Brain and CNS (1.9) Breast (9.2) Breast (98.8) Stomach (154.0)
    3 Non-Hodgkin lymphoma (0.9) Cervix uteri (5.3) Stomach (40.9) Lung (117.7)
    4 Thyroid (0.7) Stomach (4.4) Colon and rectum (39.0) Liver (74.5)
    5 Ovary (0.7) Ovary (2.7) Cervix uteri (24.2) Thyroid (69.3)
    Sites Total Male Female
    1993-1995 1996-2000 2001-2005 2004-2008 Change a) 1993-1995 1996-2000 2001-2005 2004-2008 Change a) 1993-1995 1996-2000 2001-2005 2004-2008 Change a)
    All sites 41.2 44.0 53.4 59.5 18.3 31.7 35.3 44.9 50.8 19.1 53.4 55.3 63.5 69.2 15.8
    Lip, oral cavity, and pharynx 41.1 46.7 53.7 57.5 16.4 35.8 41.1 48.9 53.1 17.3 58.1 63.8 67.3 69.3 11.2
    Esophagus 12.7 15.2 20.7 24.7 12.0 11.8 14.3 20.0 24.0 12.2 23.7 24.2 28.4 32.2 8.5
    Stomach 42.8 46.6 57.4 63.1 20.3 43.0 46.9 58.1 63.8 20.8 42.6 46.0 55.9 61.6 19.0
    Colon and rectum 54.8 58.0 66.3 70.1 15.3 55.3 59.0 68.3 72.0 16.7 54.2 56.8 63.8 67.5 13.3
    Liver 10.7 13.2 19.7 23.3 12.6 9.9 12.9 19.7 23.4 13.5 13.6 14.2 19.7 22.9 9.3
    Gallbladder b) 17.3 19.7 22.3 24.9 7.6 16.6 20.3 22.9 25.9 9.3 18.0 19.1 21.7 23.9 5.9
    Pancreas 9.4 7.6 7.5 7.6 -1.8 8.8 7.3 7.5 7.3 -1.5 10.1 8.1 7.5 7.9 -2.2
    Larynx 59.7 62.3 65.9 69.2 9.5 60.2 62.8 66.5 69.9 9.7 55.4 57.8 57.5 59.1 3.7
    Lung 11.3 12.7 15.8 17.5 6.2 10.4 11.6 14.6 15.9 5.5 14.2 16.2 19.1 21.5 7.3
    Breast 77.9 83.2 88.2 89.9 12.0 75.1 85.6 86.0 81.5 6.4 78.0 83.2 88.2 90.0 12.0
    Cervix uteri 77.5 80.0 81.0 80.5 3.0 - - - 77.5 80.0 81.0 80.5 3.0
    Corpus uteri 81.5 81.8 84.5 84.6 3.1 - - - - 81.5 81.8 84.5 84.6 3.1
    Ovary 58.7 58.9 61.0 59.9 1.2 - - - - 58.7 58.9 61.0 59.9 1.2
    Prostate 55.9 67.2 79.5 86.2 30.3 55.9 67.2 79.5 86.2 30.3 - - - - -
    Testis 85.4 90.4 90.4 91.2 5.8 85.4 90.4 90.4 91.2 5.8 - - - - -
    Kidney 62.0 66.1 73.2 76.4 14.4 60.8 64.4 72.6 76.4 15.6 64.5 69.7 74.3 76.4 11.9
    Bladder 69.1 73.1 75.3 76.1 7.0 70.0 74.8 77.1 77.8 7.8 65.5 66.3 68.1 68.9 3.4
    Brain and CNS 38.5 39.0 40.4 42.0 3.5 37.2 37.5 39.7 41.3 4.1 40.2 40.7 41.1 42.7 2.5
    Thyroid 94.2 94.9 98.1 99.3 5.1 87.2 89.5 95.6 98.3 11.1 95.4 95.9 98.5 99.5 4.1
    Hodgkin lymphoma 68.0 71.2 75.9 80.9 12.9 67.6 68.1 73.9 78.9 11.3 68.6 77.4 80.0 84.7 16.1
    Non-Hodgkin lymphoma 46.6 50.8 59.6 62.8 16.2 45.3 48.9 57.7 61.0 15.7 48.7 53.5 62.1 65.0 16.3
    Multiple myeloma 22.1 19.8 28.9 33.2 11.1 21.1 17.8 29.1 33.7 12.6 23.3 22.1 28.6 32.8 9.5
    Leukemia 26.5 33.3 41.2 44.9 18.4 26.2 32.3 41.1 44.5 18.3 26.8 34.6 41.4 45.4 18.6
    Other and ill-defined 42.1 45.9 55.0 60.4 18.3 37.4 42.4 51.4 56.3 18.9 47.4 50.0 59.1 64.9 17.5
    Sites Crude mortality rates/100,000 Age-standardized mortality rates/100,000 a)


    Both sexes Male Female Both sexes Male Female
    All sites 1,466.8 1,350.4 1,583.7 1,107.4 1,145.0 1,136.2
    Lip, oral cavity, and pharynx 22.9 31.2 14.5 17.4 25.8 10.5
    Esophagus 10.6 19.1 2.0 8.0 16.4 1.3
    Stomach 272.7 362.0 183.0 203.2 302.0 123.6
    Colon and rectum 208.5 244.2 172.8 155.1 206.1 115.8
    Liver 72.9 109.4 36.3 56.0 90.2 25.9
    Gallbladder b) 20.1 20.5 19.7 14.8 17.5 12.9
    Pancreas 9.7 10.8 8.6 7.2 9.0 5.8
    Larynx 12.9 24.1 1.7 9.7 20.8 1.0
    Lung 70.7 94.8 46.5 52.8 81.1 31.2
    Breast 160.9 1.5 320.9 118.5 1.3 232.2
    Cervix uteri 67.0 - 134.3 49.1 - 95.1
    Corpus uteri 18.4 - 36.9 13.9 - 27.2
    Ovary 19.7 - 39.5 15.4 - 30.4
    Prostate 48.5 96.7 - 34.6 86.3 -
    Testis 2.8 5.7 - 2.6 5.2 -
    Kidney 30.9 41.5 20.2 23.9 34.2 15.0
    Bladder 37.0 60.0 13.9 26.9 51.8 8.6
    Brain and CNS 12.7 13.3 12.1 11.6 12.4 10.8
    Thyroid 218.0 61.6 375.1 163.1 47.1 277.7
    Hodgkin lymphoma 2.5 3.2 1.9 2.2 2.8 1.7
    Non-Hodgkin lymphoma 32.7 35.8 29.5 26.1 30.5 22.3
    Multiple myeloma 5.0 5.2 4.7 3.8 4.4 3.3
    Leukemia 20.1 22.0 18.2 20.0 22.0 18.1
    Other and ill-defined 89.7 87.9 91.5 71.1 78.0 65.7
    Table 1 Number of cancer incidence cases, deaths, and prevalent cases by sex during 2008 in Korea

    CNS, central nervous system. a)10-yr prevalent cases: limited-duration prevalent cases on January 1, 2009. These are patients that were diagnosed between January 1, 1999 and December 31, 2008 and were alive on January 1, 2009. Multiple primary cancer cases were counted multiple times, b)Includes gallbladder and other/unspecified parts of biliary tract.

    Table 2 Crude and age-standardized cancer mortality rates by sex during 2008 in Korea

    CNS, central nervous system. a)Age adjusted to the World Health Organization (WHO) world standard population, b)Includes gallbladder and other/unspecified parts of biliary tract.

    Table 3 Ten leading causes of death during 2008 in Korea

    Source: Mortality Data, 2008, Korea National Statistical Office. a)Age adjusted to the World Health Organization (WHO) world standard population.

    Table 4 Crude and age-standardized cancer mortality rates by sex during 2008 in Korea

    CNS, central nervous system. a)Age adjusted to the World Health Organization (WHO) world standard population, b)Includes gallbladder and other/unspecified parts of biliary tract.

    Table 5 Trends in cancer incidence rates in both sexes during 1999-2008 in Korea

    CNS, central nervous system. a)Annual percent change (APC) using age-standardized incidence based on the World Health Organization (WHO) world standard population, b)The APC is significantly different from zero (p<0.05), c)Includes gallbladder and other/unspecified parts of biliary tract.

    Table 6 Trends in cancer incidence rates in males during 1999-2008 in Korea

    CNS, central nervous system. a)Annual percent change (APC) using age-standardized incidence based on the World Health Organization (WHO) world standard population, b)The APC is significantly different from zero (p<0.05), c)Includes gallbladder and other/unspecified parts of biliary tract

    Table 7 Trends in cancer incidence rates in females during 1999-2008 in Korea

    CNS, central nervous system. a)Annual percent change (APC) using age-standardized incidence based on the World Health Organization (WHO) world standard population, b)The APC is significantly different from zero (p<0.05), c)Includes gallbladder and other/unspecified parts of biliary tract.

    Table 8 Five major sites of cancer incidence by age group and sex during 2008 in Korea

    CNS, central nervous system. a)Kidney and testis are same rank.

    Table 9 Trends in the 5-yr relative survival rates (%) by year of diagnosis during 1993-2008 in Korea

    CNS, central nervous system. a)Change in the 5-yr relative survival between 1993-1995 and 2004-2008 as a percentage, b)Includes gallbladder and other/unspecified parts of biliary tract.

    Table 10 Crude and age-standardized cancer 10-yr prevalent rates on January 1, 2009 by sex during 2008 in Korea

    CNS, central nervous system. a)Adjusted to the World Health Organization (WHO) world standard population, b)Includes gallbladder and other/unspecified parts of biliary tract.


    Cancer Res Treat : Cancer Research and Treatment
    Close layer
    TOP